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 PSYCHOLOGICAL DYSFUNCTION, DRUG TREATMENT ENGAGEMENT, AND
HIV RISK BEHAVIOR AMONG METHADONE MAINTAINED CLIENTS 
 
Latika D. Davis-Jones, Ph.D., MPH, MSW  impact of opiate addiction on public health has been severe with its links to disease, death, 
nomics, and mental health problems. Many opiate addicts inject drugs several times each day 
ch has been associated with many infectious diseases, including: Hepatitis B and C, 
rculosis, and HIV/AIDS (National Institutes on Drug Abuse, 2000). This study investigated 
relationships of psychological dysfunction, drug treatment engagement, HIV risk reduction 
udes, and HIV risk behaviors among methadone maintained clients. It was guided by the 
S Risk Reduction Model (ARRM), a heuristic device that helps to explain/predict behavior 
nge of individuals in relationship to sexual and injection drug use transmission of HIV/AIDS. 
A quantitative cross-sectional research design was utilized to examine the relationship 
een psychological dysfunction and HIV risk behavior among methadone maintained clients 
 how drug treatment engagement and HIV risk reduction attitudes affect this relationship. A 
l of 200 participants who were at least 18 years old and were enrolled in methadone 
ntenance treatment were included in this investigation. 
This study found that 60% of the participants had experienced moderate to high levels of 
chological dysfunction. Psychological dysfunction was categorized into past depression, 
iety, and hostility symptoms.  
iv 
Multiple regression analyses showed that overall psychological dysfunction and drug 
treatment engagement predicts HIV risk behavior among methadone maintained individuals 
(F=13.06; p<.000). However, when the standardized regression coefficients of the individual 
independent variables were examined, only drug treatment engagement was found to 
significantly contribute to the prediction of HIV risk behavior ($=-.22; p< .01), indicating that 
those who reported higher levels of treatment engagement had lower levels of HIV risk behavior. 
The mediating role of drug treatment engagement on the relationship between 
psychological dysfunction and HIV risk behavior was supported. Although, it was not supported 
for HIV risk reduction attitudes, analysis showed that HIV risk reduction attitudes were 
moderately and significantly correlated with HIV risk behavior. 
The findings of this study provide social work and public health practitioners who work 
in the field of drug and alcohol treatment and HIV prevention with vital information This study 
underscores the need for early identification and modification of psychological problems among 
methadone maintained individuals. Drug treatment provides a vital opportunity to address 
psychological problems and HIV risk behavior, there is an irrefutable need for the social work 
and public health professionals to further research and develop/refine interventions to prevent the 
spread of HIV disease among this population. Early screening and treatment of psychological 
problems may help increase drug treatment engagement rates which may reduce HIV risk 
behavior and ultimately save lives among methadone maintained clients.  
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1.0  INTRODUCTION 
1.1 STATEMENT OF PROBLEM 
It has been estimated that over one million people in the United States are addicted to heroin, 
prescription painkillers, and other opiates (National Drug Intelligence Center, 2004). In fact, 
opiate addiction has surpassed cocaine addiction to become the most common substance abuse 
diagnosis behind alcoholism (DHHS, 1999).  
Opiate addiction severely impacts public health and is related to disease, premature death, 
and mental health problems. More specifically, opiate addicts are significantly more likely than 
the general population to acquire infectious diseases, including: Hepatitis B and C, tuberculosis, 
and HIV/AIDS (National Institutes on Drug Abuse, 2000). Specifically, about one third of adult 
and adolescent HIV/AIDS cases in the U. S. have been associated with injection drug use and the 
prevalence rate of Hepatitis C is up to 90% among injection drug users (National Institutes of 
Health, 1999). Opiate related deaths (over-doses) increased by 74% during the 1990s and 
continue to grow in the 2000s. The economic cost of opiate addiction when left untreated (with 
its links to illness, crime, and mental health) is an estimated $20 billion each year (National 
Institutes of Health, 1997).   
Psychological problems are common among individuals addicted to opiates (Croughan et 
al., 1982; Rounsaville et al., 1982; Kranzler & Liebowitz, 1988; Brienza et al., 2000). The 
1 
presence of a psychological problem in addition to a drug problem (co-occurring disorders) can 
have serious implications on the adoption of preventive health behavior. For example, some 
psychological problems (depression and anxiety) may trigger drug cravings and have been 
associated with increased sexual risk behavior and higher levels of injection-related risk taking 
which ultimately increases the risk for contracting HIV (Marks et al., 1998; Thompson et al., 
1996).  
Within the past 5 years, many of the new HIV cases have been among injection drug 
users and it has been estimated that approximately 40,000 new infections occur each year 
(Center for Disease Control, 2005). Although, injection drug use (needle sharing) is the primary 
mode of HIV transmission among drug users, sexual transmission of HIV is also high among 
drug using individuals (Kral et al., 2001; Strathdee et al., 2001). Transmission of HIV can be 
reduced among opiate addicts by making drug treatment available to those that want help. 
According to the World Health Organization, drug treatment as a prevention strategy for 
HIV/AIDS among opiate addicts is much more effective than typical prevention efforts that only 
focus on safer needle and/or safer sex practices. Drug treatment have been found to reduce drug 
use, injection frequency, and associated HIV risk-taking behavior (World Health Organization, 
2004).     
Past research suggests that individuals who enter drug treatment with more severe 
psychological problems perform worse during drug treatment (Woody et al., 1984).  Specifically, 
these individuals have more negative drug treatment experiences (Camacho, Brown & Simpson, 
1996). For example, depressed individuals are less likely to abstain from drugs and the 
complexity and severity of their psychological problems can hinder their efforts to reduce drug 
use and to engage in drug treatment (Kosten et al., 1986; Simpson, 2001). Psychological 
2 
problems, in addition to opiate addiction and lack of drug treatment engagement, may continue 
to put these individuals at risk for contracting and spreading HIV (Rao et al., 2004). Drug 
treatment provides an opportunity to address psychological problems that may otherwise go 
untreated. If untreated, psychological problems may affect readiness to modify HIV risk 
behaviors, a main principle of behavior change models. Accordingly, enrolling opiate addicts in 
drug treatment allows for assessment and treatment of psychological problems and may help in 
the adoption of HIV risk reduction methods. 
1.2 PURPOSES OF THE STUDY 
The purpose of this study is to examine the extent to which psychological problems, drug 
treatment engagement, and HIV risk attitudes impact HIV risk behavior in a sample of 
methadone maintained clients. Specifically I: (1) First examine the prevalence of psychological 
dysfunction (i.e., depression, anxiety, and hostility), drug treatment engagement (i.e., counseling 
rapport, treatment satisfaction, and treatment participation), and the level of HIV risk behavior 
(injection drug use, non-injection drug use, and sexual behavior) in the sample, (2) then I 
examine the relationship between psychological dysfunction and HIV risk behavior, (3) next I  
explore the relationship between psychological dysfunction and drug treatment engagement, (4) I 
then investigate the direct and indirect effects of drug  treatment engagement on HIV risk 
behavior, (5) and finally, I test the direct and indirect effects of HIV risk attitudes on HIV risk 
behavior.   
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1.3 SIGNIFICANCE OF THE STUDY TO SOCIAL WORK AND PUBLIC HEALTH 
Currently, relatively little research examines HIV risk-taking behavior of individuals who have 
co-occurring disorders (substance use disorder and mental health disorder- i.e. depression, 
anxiety, hostility). Although there are studies that focus on the problems that opiate addicts face, 
there is little research that identifies psychological, risk reduction attitudes, and behavioral 
predictors of HIV risk behavior among this population. Many studies that examine HIV risk 
behavior either typically focus on sexual behaviors or on injection drug use behaviors. This study 
will not only focus on both sexual and injection drug use risk behavior but will also include non-
injection drug use risk (due to its disinhibiting effects) when examining HIV risk behaviors. In 
addition, to my knowledge very few studies have focused on more than one psychological 
problem when examining the relationship between psychological dysfunction and HIV risk 
behavior (Brooner et al., 1997; Darke & Ross, 1997; Rousaville et al., 1982). There are many 
psychological problems (anxiety, depression, hostility) common among opiate addicts. In order 
to capture the problems that addicts face this study will examine multiple psychological 
problems (independently and as a whole-psychological dysfunction) and will build on existing 
research by examining possible mediators in such relationships (i.e., drug treatment engagement 
and HIV risk attitudes).          
The results of this study may help professionals identify and modify the predictors of 
HIV risk behavior, which may help prevent the transmission of HIV and ultimately save lives. 
Given the importance of drug treatment, as an opportunity to address drug use and sexual 
behavior as routes of HIV transmission, there is an irrefutable need for the social work/public 
4 
health profession to further research and determine the unique needs of clients with co-occurring 
disorders. 
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2.0  LITERATURE REVIEW 
2.1 CO-OCCURRING DISORDER 
Co-occurring disorder refers to a substance use disorder and a psychological disorder 
(SAMHSA, 2006). In 2002, 33.2 million adults in the United States aged 18 or older had a 
psychological disorder or a substance related disorder (SAMSHA, 2006). Overall, 13.4 million 
(40.4%) had only a psychological disorder, 15.7 million (47.4%) had only a substance related 
disorder and 4.0 million (12.2%) had both psychological disorder and a substance related 
disorder (i.e., co-occurring disorder) (SAMHSA, 2006). Adults with substance related disorders 
were almost three times more likely to have serious mental illness (20.4%) than those who did 
not have a substance related disorder (7.0%) (SAMHSA, 2006). The prevalence of psychological 
disorders was 19.0 percent among those with alcohol dependence or abuse, 29.1 percent among 
those with illicit drug dependence or abuse, and 30.1 percent among adults who had both drug 
and alcohol dependence or abuse (SAMHSA, 2006).  
The co-occurrence of psychological disorders and substance related disorders is a 
significant problem for people in drug and alcohol treatment. In fact one of the strongest 
predictors of relapse and other unfavorable drug treatment outcomes is the co-occurrence of a 
psychological disorders and a substance use disorder (Hawkins et al., 2005). 
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2.2 METHADONE MAINTENANCE TREATMENT 
Since the 1960s, methadone maintenance treatment (MMT) has been the most commonly used 
and the most effective treatment for opiate addiction (Ball, 1991). With the high prevalence of 
HIV/AIDS among opiate/injection drug users (IDUs), increased interest in MMT has grown 
among policy makers, public health professionals, and non-methadone prescribing drug 
treatment facilities. Methadone maintenance treatment has been found to significantly reduce the 
frequency of injection drug use and has also been shown to decrease sexually related high-risk 
behavior (Grella & Wugalter, 1997).  
Methadone is a long-acting narcotic medication that suppresses symptoms of opiate 
withdrawal and reduces cravings for opiates without causing euphoric or sedative effects (Dole, 
1998). Methadone maintenance treatment is designed to reduce illegal and harmful opiate use 
along with the many problems (e.g. crime, death, disease) associated with its addiction. The 
primary goals of MMT are to decrease and/or eliminate opiate use, to reduce criminal behavior, 
to and prevent HIV/AIDS.  For opiate addicts, methadone maintenance treatment is an important 
point of contact with service providers, because it provides an opportunity to educate drug users 
about harm reduction approaches (condom usage, needle exchange, beneficial effects of 
methadone, effective needle/crack pipe cleaning methods) and to address their drug problems 
and mental health needs (SAMHSA, 2005). 
Due to past practices and misperceptions, MMT has yet to be widely accepted as a 
credible treatment modality. Throughout its history, MMT has been the recipient of pessimistic 
attitudes and actions by its opponents. Some of the public has opposed the use of methadone for 
treating opiate addiction and government policies have prevented access to MMT in many 
communities.  Many opponents of MMT perceive opiate addiction as a “bad habit” or moral 
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flaw, and dismiss MMT as a useless, addictive narcotic substitution therapy. Conversely, others 
argue that MMT is not a mere replacement for other illicit opiates and that it does not merely 
substitute one addiction for another (NIH, 1997). Although methadone can cause physical 
dependence, its effects on the brain contrast sharply with the addictive cycle of highs and lows 
produced by other opiates (SAMHSA, 2003). A key benefit of MMT is that methadone taken 
orally once a day permits clients to have a stable lifestyle (e.g., no drowsiness, no cravings, or 
withdrawal symptoms). This stability provides the opportunity for the addict to stop habitual 
drug seeking and taking, engaging in HIV risk behaviors, and committing crimes (NIH, 1999).   
In addition to its benefits for the individual user, methadone maintenance treatment is a 
more cost effective alternative for opiate addiction than incarceration or hospitalization. For 
example, it estimated that it costs approximately $42,000 per year to leave a drug abuser 
untreated in the community, $40,000 if the addict is incarcerated, and about $4,000 if the addict 
is admitted to a MMT program (SAMHSA, 1999). Further, when addicts are enrolled in MMT 
their illegal activity declines by 52% and full time employment increases by 24%. Taken as a 
whole, methadone maintenance treatment has helped millions of people recover from opiate 
addiction; allowing addicts to stop criminal behavior, restore their health, mend family and social 
relationships, and gain employment (SAMHSA, 1999).  
2.3 HIV RISK BEHAVIOR 
The ways in which injection drug use puts individuals at risk of HIV varies.  For example, one 
may be put at risk by sharing needles or drug equipment (spoons, cotton, crack pipes, and 
cookers) used to prepare drugs for use.  HIV risk may also occur by injecting drugs with a 
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contaminated syringe. Indirect HIV risk transmission may occur when drugs are contaminated in 
the mixing process. HIV injection risk may also be related to frequency of injecting drugs along 
with where the individual gets his or her needles (i.e., shooting galleries, partner/spouse, 
pharmacy, or network of drug using friends).  
Sexual behavior is another route of HIV risk transmission. Sexual activity provides a path 
for the exchange of body fluids. High risk sexual behavior includes: trading sex for drugs or 
money, having multiple sex partners, having sex without a condom, having sex with a known 
drug user, having anal sex, and having sex while high on drugs or alcohol.  Non-injection drug 
use is also associated with HIV risk behavior, either as a result of increased libido caused by 
certain drugs like crack cocaine and methamphetamine or by drug or alcohol use causing 
individuals to be disinhibited (Marks et al., 2006). 
2.4 PSYCHOLOGICAL DYSFUNCTION AND HIV RISK BEHAVIOR 
The relationship between psychological dysfunction and HIV risk behavior has been studied by a 
number of researchers. These studies have suggested that psychological problems predict drug-
related and sex-related HIV risk behavior (Avants et al., 2000; Williams & Latkin, 2005; 
Metzger et al., 1991; Stein et al., 2003; Perdue et al., 2003). In the addiction literature, 
psychological disorders(e.g., depression, antisocial personality disorder, and social anxiety) and 
personality style (neuroticism and conscientiousness) have been identified as some of the 
predictors of HIV risk behavior among drug users (Bronner et al., 1997; Camacho et al. 1996; 
Metzger et al., 1991). For example, a study that examined the relationship psychological 
dysfunction and HIV risk behavior among 834 opiate drug users in methadone treatment found 
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that psychological dysfunction was significantly related to needle sharing risk in terms of 
injecting with used needles, sharing works (drug paraphernalia), and sharing needles with an 
unfamiliar person (Camacho, Brown, & Simpson, 1996). Psychological problems were also 
associated with sex risk in terms of number of sex partners, unprotected sex with known 
injection drug users, and prostitution (Camacho, Brown, & Simpson, 1996).  
The results of a recent meta-analytic review that examined whether depressive 
symptomatology, anxiety, and anger were associated with sexual behaviors of 34 studies of 
various populations (injection drug users, gay men, youth, and women), provided little support 
that psychological problems were associated with sex risk behavior.  The authors suggested that 
the lack of association between psychological problems and sexual risk behavior may be the 
result of research designs (cross-sectional) that past research used. One key limitation of this 
study is that it did not address drug-related HIV risk behavior, which is characteristic of the 
various sample types that were included in their study (youth, homosexuals, women, and 
injection drug users). Because of this limitation the extent to which there is an association 
between psychological problems and HIV risk behavior has yet to be determined.  In fact, more 
recent studies have found a relationship between psychological problems and HIV risk behavior 
among drug users (Williams & Latkin, 2005; Perdue et al., 2003; Stein et al., 2003; Crepaz & 
Marks, 2001). 
2.4.1 Depression and HIV Risk Behavior 
In addition to the high prevalence of HIV/AIDS among drug using populations, depression is 
also common (Brooner et al., 1997; Darke & Ross, 1997; Rousaville et al., 1982).  Past studies 
have shown that lifetime and current rates of major depression for this population are 20% to 
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50% and 10 to 20% respectively (Nunes et al., 1994; Hasin & Nunes, 1998). Depression has 
been shown to impede the adoption of protective HIV behavior. Orr et al. (1994) posit that 
depression affects the adoption of health behaviors because it produces hopelessness and despair, 
which in turn, impede behavior change. Other research suggests that depression may trigger drug 
craving for those enrolled in drug treatment. This drug craving may cause the individual to 
relapse, which is associated with continued HIV risk taking behavior through injection drug use 
practices, non-injection drug use, and risky sexual behavior (Stein et al., 2003). 
A cross-sectional study of black women  attending urban health centers who had higher 
levels of depressive symptomatology were significantly more likely than women with lower 
depressive symptoms to report more risk factors for HIV (Orr et al., 1994). Similarly, 
longitudinal studies of the depression and HIV risk behavior link found that injection drug users 
with higher levels of depressive symptoms at baseline and at a six month follow-up significantly 
predicted increased changes in injection drug use and HIV risk behaviors (Hawkins et al., 1998; 
Latkin & Mandell, 1992). 
Other studies found that among 1228 injection drug users completing the Center for 
Epidemiologic Studies Depression Scale (CES-D), higher scores were significantly associated 
with sharing needles, sharing drug equipment, and practicing backloading (use of a syringe to 
divide drugs  before injection). In addition, a longitudinal study examining the relationship 
between depressive symptoms and sexual HIV risk behaviors among 332 inner-city drug users 
found that high depressive symptoms are causally related to having sex with mutiple partners and 
having sex with known injection drug and crack users (Perdue et al., 2003; Williams & Latkin , 
2005). A similar relationship between depression and HIV risk behavior was found among 405 
drug treatment clients. Specifically, researchers found that clients with higher scores on the Beck 
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Depression Inventory were more likely to engage in risky HIV related drug injection practices 
than those with lower scores (McCusker et al., 1995). However, this relationship did not stand 
true when analyzing the relationship between depression and HIV sexual risk behavior.      
2.4.2 Anxiety and HIV Risk Behavior 
The prevalence of mood and anxiety disorders are more pronounced among those addicted to 
opiates when compared with the general population.   A study of 533 opiate addicts receiving 
treatment found that 70% met the criteria for having a current psychiatric disorder, over 11% met 
the criteria for having anxiety disorder (Rounsaville et al., 1982). In a more recent study of 116 
respondents, which measured the prevalence of anxiety disorder in a substance dependent 
population, more than half of the sample reported heroin as their drug of choice with 11% 
reporting use of heroin intravenously. In this sample, 39% had a current diagnosis of anxiety 
disorder, and 53% showed lifetime prevalence for anxiety disorder (Franken and Hendricks, 
2001). 
A small number of studies have demonstrated a positive relationship between anxiety and 
HIV risk behavior. For example, Malow et al. (1992) found that among 170 treatment-seeking 
drug abusers, those reporting higher anxiety scores reported engaging in significantly more HIV 
needle risk behaviors (frequency of injection drug use, sharing needles, and lack of clean 
needles). Specifically, a high anxiety group created from anxiety scores on the State-Trait 
Anxiety Scale was significantly more likely to be engaged in injection risk behavior (a composite 
index) than either the moderate or low anxiety group. However, sexual risk behavior (a 
composite index) was not related to higher anxiety scores among this sample. 
12 
Another study examined the relationship between psychological functioning and HIV risk 
behavior among 194 injection drug users (Simpson, Knight, and Ray, 1993). This study explored 
measures of anxiety, depression, decision-making, and self-esteem in relationship to HIV 
injection and sex risk behavior. In regards to anxiety, needle risk behavior was associated with 
anxiety but was not related to sex risk. Similarly, a study examining the relationship of 
psychological dysfunction and HIV risk behavior among opiate drug users in methadone 
treatment, found that anxiety (included in an overall measure of psychological dysfunction) was 
significantly related to needle sharing risk behaviors including injecting with used needles, 
sharing works (drug paraphernalia), and sharing needles with an unfamiliar person. Anxiety was 
also associated with sex risk in terms of number of sex partners, unprotected sex with known 
injection drug users, and prostitution (Camacho, Brown, and Simpson, 1996).              
2.4.3 Hostility and HIV Risk Behavior 
Past research has shown that opiate addicts have a high prevalence of elevated levels of hostility 
(Chien 1980; Ahmad, Ramalingum, & Ahmad, 1984). Research among 727 former methadone 
treatment clients found that increased levels of hostility predicted increased drug use after 
treatment. Specifically, former methadone clients with higher levels of hostility were more likely 
to use cocaine/crack on a weekly basis. In fact, each additional one-point increase for hostility 
almost tripled the odds of weekly cocaine/crack use. Those who used cocaine/crack are said to be 
at high risk to contract HIV because many of them often trade sex for drugs or money with 
multiple partners (Rao, Broome, and Simpson, 2004). 
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Another study on the relationship between hostility and drug use among 323 drug-users 
found that increased levels of hostility were significantly associated with HIV injection risk 
behavior (Metzger et al., 1991). Similarly, among 255 in and out-of-treatment drug users, those 
who shared needles had significantly higher scores on a hostility measure and were more likely 
to have HIV (Woody et al., 1997). In sum, past research finds that psychiatric severity is a 
significant predictor of injecting; especially needle sharing, which is probably the single most 
risky behavior among drug users (Stein, 2003).             
2.5 DRUG TREATMENT ENGAGEMENT AND HIV RISK BEHAVIOR 
Drug treatment is potentially a critical HIV prevention strategy. The most effective way for drug 
users to reduce their risk for contracting HIV through contaminated needles and multiple sexual 
contacts is to stop using drugs, and if it is not possible, drug users need help to reduce their 
frequency of injecting, drug use, and engaging in unprotected sex (World Health Organization, 
2004). Drug treatment can interrupt HIV transmission by reducing drug-related HIV risk 
behavior, including frequency of drug use, injection drug use, or sharing of needles/drug 
equipment. Although not the primary goal, drug treatment programs also have the potential to 
reduce risk behaviors associated with sexual transmission of HIV, such as sexual activity 
triggered by disinhibition or other drug effects, and engaging in sex in exchange for drug or 
money (Sorenson and Copeland, 2000). However, the full benefits of drug treatment may not be 
experienced if the individual does not engage in the drug treatment process. 
Drug treatment engagement is the process of developing a trusting relationship between a 
counselor and client and adhering to the treatment process. The counselor establishes regular 
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contact and a helpful relationship with the client in order to foster recovery from drugs and 
alcohol (Simpson, 2004). Drug treatment engagement is measured primarily by program 
participation and the formation of a therapeutic relationship with an assigned counselor 
(counseling rapport). Program participation can include individual and group therapy session 
attendance as well as assessments of psychological engagement in these sessions. The 
therapeutic relationship is believed to be the crux of effective drug treatment (Simpson, 2004). In 
many states, federal guidelines are in place to ensure that clients are receiving quality drug 
treatment services.  
Specifically, federal law requires that all methadone maintenance programs provide 
adequate medical, counseling, vocational, educational, and other assessment and treatment 
services. Under the counseling mandate it is required that methadone programs provide 
counseling on preventing exposure to, and transmission of, HIV disease for each patient admitted 
or readmitted to maintenance or detoxification treatment. Additionally, it is mandated that all 
methadone programs provide substance abuse counseling. This counseling has to be provided by 
qualified counselors that have the ability to assess the psychological (such as depression) and 
sociological background of client in order to contribute to the appropriate treatment plan for the 
client and to monitor client progress (Federal Register, 2001). The requirements of federal drug 
treatment policies are central to the variables of the present study: assessment of psychological 
background of patient (i.e., depression, anxiety, hostility), treatment engagement (effective 
counseling--methadone treatment), and HIV risk assessment. 
Past research suggests that drug treatment engagement is a significant predictor of HIV 
risk behavior. More specifically, studies of methadone clients have found that higher levels of 
drug treatment engagement significantly predicted lower levels of injection drug use, heroin use, 
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alcohol and cocaine use, all of which are known drug-related HIV risk factors (Simpson, Joe, 
Rowan-Szal, & Greener, 1995; Simpson, Joe, Rowan-Szal, & Greener, 1997; Joe et al., 2001). 
Another study that examined the association between counseling rapport and drug abuse 
treatment outcomes among 354 clients in community-based nonprofit programs and 223 private 
for-profit program clients found that lower levels of rapport during treatment predicted worse 
treatment outcomes, including more cocaine use and criminality (i.e., selling drug, theft, 
prostitution) both by itself and after adjustment for length of time in treatment and treatment 
satisfaction (Joe et al., 2001). 
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3.0  THEORY  
3.1 AIDS RISK REDUCTION MODEL (ARRM) 
The AIDS Risk Reduction Model (ARRM), is a widely used theorectical framework that 
attempts to explain and predict behavior change efforts of individuals in relationship to sexual 
and injection drug use transmission of HIV/AIDS. A three-stage model, the ARRM is derived 
from previous models that examine social psychological problem solving, and incorporates 
several variables from other behavior change theories, including the Health Belief Model, self-
efficacy theory, emotional influences, and interpersonal processes. The three stages of the 
ARRM include: 1) recognition and labeling of one’s behavior as high risk, 2) making a 
commitment to reduce high-risk sexual/drug use contacts and to increase low-risk activities; 3) 
seeking and taking action (enactment) to obtain these goals (Catania, Kegeles & Coates, 1990).  
The ARRM’s premise is that to prevent HIV infection, individuals with high-risk 
behaviors must perceive that their sexual and drug use behaviors as problematic and that their 
behavior place them at risk for contracting HIV.  In addition, the individual must be willing to 
change behaviors that place them at risk. The change process may require the individual to weigh 
the benefits of changing the risky behavior against the cost of changing such behavior. Lastly, 
the individual will need to enact low risk activities. This effort may take several undertakings. 
The individual may employ solutions through measures of self-help and informal/formal social 
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support (professional services- i.e., drug treatment). However, barriers that the individual faces 
such as finances, environmental factors, sexual/drug using partners, and psychosocial barriers 
may impede these efforts. This overall process (labeling, commitment, and action) may not be 
unidirectional or nonreversible (Catania, Kegeles & Coates, 1990). For example, drug users may 
be immensely challenged in changing their drug use behavior, and come to relabel their drug 
using activities as unproblematic or drug users may reduce their commitment to change. In the 
case of persons in MMT, individuals may come into drug treatment viewing their situation as 
problematic but after several relapses individuals may decide that the recovery/treatment process 
is more difficult than they expected and thus they decide to lower their commitment to MMT 
ultimately putting them at risk for contracting HIV. 
Progression through the ARRM stages is dependent on the influence of several 
psychosocial factors. These factors are: susceptibility, HIV transmission knowledge, aversive 
emotional states, social factors, perceptions of enjoyment and risk reduction, self-efficacy, sexual 
communication skills, and help-seeking behavior (Catania, Kegeles & Coates, 1990).  Some of 
these factors may not be specific to any one stage but are considered to either motivate or hinder 
movement across the stages of ARRM.  
In stage 1 of ARRM, recognition and labeling of one’s behavior as high risk (or 
problematic), is said to be influenced by three factors. The first factor is the individual’s 
knowledge of sexual activities associated with HIV transmission (Catania, Kegeles & Coates, 
1990). It is hypothesized that knowledge of drug use activities associated with HIV transmission 
influences recognition and labeling behavior as high risk. Second, recognition and labeling one’s 
behavior is also influenced by one’s perceived susceptibility of contracting HIV. It is 
hypothesized that individuals must perceive themselves as being at risk for HIV infection in 
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order for them to change their behavior to lower risk activities (Catania, Kegeles & Coates, 
1990). Third, the individual must believe that having HIV/AIDS is undesirable. If the individual 
does not place value on their health and does not believe that having AIDS is an undesirable 
health condition the person is less likely to change their behavior than someone whom believes 
that contracting HIV is undesirable (Catania, Kegeles & Coates, 1990). According to the ARRM 
Model, when drug users learn that HIV is transmitted by sex and drug use activities (i.e. – unsafe 
sex, sharing needles, crack pipes, and drug paraphernalia), they examine their behavior, label 
their behaviors as risky, and as a result feel worried or apprehensive about the behavior and their 
susceptibility of contracting HIV. When this process occurs, the theory suggests that drug users 
will label their behavior as problematic and be more likely to make a commit to changing their 
behavior. However, it should be noted that drug users’ sexual and drug using partners may 
seriously impact their labeling process, leading user to relabel their behavior as being low risk or 
to use other coping mechanisms such as denial or avoidance to deal with the challenging issue of 
behavior change (Catania, Kegeles & Coates, 1990).  
The second stage of ARRM is based on social cognitive theory. Social cognitive theory 
posits that human behavior is a triadic, dynamic, and reciprocal interaction of personal factors, 
behavior, and the environment (Bandura, 1989). In stage 2 of ARRM--commitment to change, 
drug users decide to make behavioral changes and strongly commit to that decision. This 
decision making process may yield other outcomes such as indecision, non-action, or continued 
involvement with the problem behavior. There are several factors that are said to influence goal 
achievement within this stage and movement unto the next stage. The hypothesized influences 
are: cost and benefits, enjoyment, response efficacy, and self-efficacy. For example, knowledge 
of health utility and enjoyability of a sexual or drug use practice, as well as social factors (peer 
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norms and social support), are believed to influence an individual’s cost and benefit and self-
efficacy beliefs.  Self-efficacy in relationship to this study will examine drug user’s confidence 
in their ability to exert control over injection, drug, and sexual risk taking. In regards to response 
efficacy, which is central to the Health Belief Model and efficacy theory, this study examines 
how drug users perceive the effectiveness of adopting safer sex and drug use practices in 
relationship to reducing their risk of contracting HIV.  The degree of commitment that drug users 
have in adopting safer sex and drug use practices may be increased when those practices are 
viewed as effective (Catania, Kegeles & Coates, 1990). 
The third stage of ARRM--taking action, happens once individuals have made a 
commitment to reducing high-risk behavior. This stage is composed of three phases, which 
include information seeking, obtaining remedies, and enacting solutions. An individual may 
complete phases concurrently or phases may be skipped entirely.  For example,  drug users may 
begin to get ideas and solicit the opinions of others on ways to change their high risk behavior or 
they may move directly to enacting a solution given that the drug user has a family member who 
is a diabetic (has access to sterile needles) and this family member has agreed to give the drug 
user their supply of extra needles.  
Several factors are said to influence this stage of the model. Social networks and 
problem-solving choices (self-help, informal and formal support) are said to influence this stage 
by the fact that people with problems utilize a variety of strategies to solve such problems. For 
example, drug users may choose to do nothing about their risky behaviors or because of the fact 
that their behavior is more stigmatized than that of those who do not use drugs, many may be 
more likely to rely on self-help solutions than informal or formal support. Other factors said to 
influence the different stages of the ARRM are: prior experiences with problems and solutions, 
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self-esteem, requirements of acquiring help, ability to communicate verbally with sex and drug 
using partners, and sex and drug using partner’s personal beliefs and behaviors (Catania et al., 
1990). 
Several studies have used the ARRM to examine HIV risk behavior among injection drug 
users (Longshore, Stein, & Anglin, 1997; Longshore, Stein, Kowalewski, 1998; Malow et al., 
1994). The findings vary in regard to the usefulness of ARRM in explaining risk behavior and 
change. For example, one study suggests that individuals who believe that their current behavior 
is risky are more likely to engage in preventive health behavior (Kok et al., 1991). Other studies 
suggest that perceived risk may decrease the likelihood of an individual adopting/committing to 
preventive health behavior (Robels et al., 1995; Malow et al., 1994). Furthermore, some studies 
have suggested that the self-efficacy construct of the model actually predicts rather than prevents 
injection risk behavior (Kok et al., 1991; Longshore et al., 1997). 
In addition to the stages listed above, the developers of the ARRM identified other 
internal and external factors that may motivate individual movement across the three stages. For 
instance, aversive emotional states (e.g., depression or alcohol and drug use that blunt emotional 
states) may facilitate or hinder the labeling of one's behaviors. Leith & Baumeister (1996) 
suggest that the self-regulatory processes (one’s ability to monitor, direct, and alter one’s 
thoughts, feelings, and actions) may be disrupted when an individual experiences psychological 
problems such as depression, anxiety, and hostility. Furthermore, a study conducted by Beck 
(1967) suggested that individuals who are upset or depressed may engage in a pattern of 
destructive thoughts, which may reduce motivation to care for themselves and lead to behaviors 
(e.g., drug use, risky sex) that may compromise their personal health. 
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Moreover, studies have suggested that some psychological problems are so unpleasant to 
deal with that the discomfort experienced may cause individuals to take actions to alleviate that 
state (Morris & Reilly, 1987).  According to McKirnan et al. (1996) the idea of practicing safe 
sex or not using drugs may be in conflict with the idea of alleviating depression, because this 
type of self-regulation often takes the form of satisfying and pleasure-seeking conduct (i.e., 
unsafe sex and drug and alcohol use) due to the individual trying to divert his or her attention 
away from the negative feelings associated with the psychological problem. Conversely, there 
are other theoretical views and empirical findings that suggest that psychological problems may 
be associated with decreased HIV sexual and drug risk behavior due to the fact that the 
individual may be extremely psychologically (e.g., manic depression) impaired and does not 
have any desire to have sex or use drugs (Schwarz, 1990; Frijda, 1988).  
The studies mentioned above and others have examined the cognitive and behavioral 
factors that may impact HIV risk behavior. However, attempting to understand HIV risk by 
focusing only on rational processes may minimize irrational or psychological problems that may 
promote risky sex and drug use. As mentioned earlier, depression has been shown to impede the 
adoption of protective health factors (Orr et al., 1994). Individuals who are psychological 
impaired may be less motivated to take action (Stein et al., 2003). The ARRM states that 
individuals must be motivated in order to take action, and if not, the individual remains at risk. 
Therefore, in the case of this model I am interested in exploring whether drug users with elevated 
levels of psychological dysfunction may be less likely to adopt or have lower levels of protective 
health behavior (i.e., effective drug treatment engagement--abstinence/reduction in drug use, 
safer sex, or safer needle practices) and/or view the protective health behavior as less 
meaningful. Consequently, this lower protective health behavior potentially places the drug user 
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at a risk for higher levels of HIV risk behavior (continued drug use, unsafe sex, and unsafe 
needle practices).  
In this model, health related change occurs specifically when an individual has interest in 
and concern about the prevention strategy. An individual, whose health beliefs oppose those that 
support for example, methadone maintenance treatment, is less likely to achieve long-term 
abstinence from drug use, which may expose the individual to risky HIV behavior. Additionally, 
this model states that aversive emotional state such as depression may impede the adoption of 
preventive health behavior. For example, several studies suggest that a significant relationship 
exist between depression and HIV risk behavior- injection drug use (Brooner et al., 1997; Regier 
et al., 1990; Ross et al, 1988; Rounsaville et al, 1982). 
Additionally, dysthymic disorder, a low grade form of depression, characterized by flat 
affect, low energy and motivation, fluctuations in overall mood and chronic pessimism may have 
an effect on an individual’s capacity to adopt protective HIV behavior (American Psychiatric 
Association, 2000).  Individuals with such symptoms may continue with methadone treatment 
(appear for medication services-take methadone), but low motivation may prevent the individual 
from actively engaging in treatment (i.e., talking about feelings, learning how to analyze and 
solve problems, reducing drug use, and attending counseling sessions). 
Chronic pessimism may also hinder the individuals’ ability to trust his or her counselor, 
which is essential to establishing the foundation of counseling rapport.  Additionally, pessimism 
may also affect how the individual perceives his/her ability (self-efficacy) to make positive 
change (i.e., quitting drug use, not sharing needles, practicing safe sex methods); the individual 
may believe that they have no or little self-efficacy. Bandura (1990) suggests that an individual’s 
perceived ability  (self-efficacy) to successfully carry out a health action such as not sharing 
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needles or using a condom every time one engages in sex, greatly influences the individuals 
decision and ability to enact and sustain a changed behavior. The items mentioned above 
(treatment participation and counseling rapport in relation to motivation and pessimism) are two 
items that are central to drug treatment engagement, in this study. Drug treatment engagement 
has been found to predict the progress of individuals in drug treatment. Severity of psychological 
problems are  often a barrier to effective treatment engagement and drug treatment outcomes 
among individuals enrolled in drug treatment (Simpson, 2004). 
3.2 CONCEPTUAL FRAMEWORK 
The present study seeks to examine the effects of psychological dysfunction, drug treatment 
engagement, and HIV risk attitudes on HIV risk behavior. The conceptual framework for this 
study is directed by the AIDS Risk Reduction Model.  As indicated in the previous section, 
Catania et al. (1990) suggest that internal and external factors may motivate or hinder an 
individual’s movement across the 3 stages of the model. Aversive emotional states (e.g., 
depression, anxiety, hostility, or alcohol and drug use that blunt emotional states) may hinder the 
labeling of one's behaviors as risky. Based on the addiction literature and the review of the 
literature, there is a well-developed body of work regarding the predictors of HIV risk behaviors 
among drug users. There is sufficient evidence to suggest that higher levels of psychological 
dysfunction are associated with HIV risking behavior in drug users (Camacho et al., 1996; Darke 
et al., 1994; Woody et al. 1997). Increased levels of psychological dysfunction may hinder 
individuals from labeling their behavior as risky and may hinder the individual from moving 
across the different stages of this model. 
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Additionally, research suggests that a relationship exists between drug treatment 
engagement and drug relapse (i.e., injection and non-injection drug use). Drug relapse may place 
an individual at risk for contracting HIV (Simpson, 2004).  Engaging in drug treatment may 
motivate the individual to label their behavior as risky allowing the individual to potentially 
move across the stages of the model.  Although not the primary goal, engaging in drug treatment 
also has the potential to reduce risk behavior associated with sexual transmission of HIV, such as 
sexual activity triggered by disinhibition brought on by alcohol use or other drug effects, and 
engaging in sex in exchange for drug or money (Sorenson and Copeland, 2000).  Accordingly, in 
this study I treat level of drug treatment engagement as a predictor of HIV risk behavior.  
Although relatively few studies have explored the impact of drug treatment engagement on HIV 
risk behavior, the limited research suggests that drug treatment is significantly related to reduced 
opiate drug use and  to HIV risk behavior (injection frequency) (Marsch, 1998; Ball, et al. 1991). 
Based on the conceptual framework and the literature review conducted for this study, I will 
examine the following questions: 
1. How prevalent are psychological disorders (anxiety, depression, and hostility) and HIV 
risk behavior among an urban of sample of methadone clients? 
2. What is the bivariate relationship between level of psychological dysfunction (anxiety, 
hostility, and depression) and level of HIV risk behavior (injection drug use, non-
injection drug use, and sexual risk)?  
3. What is the bivariate relationship between treatment engagement (counseling rapport, 
treatment satisfaction, and treatment participation) and HIV risk behavior?  
4. What is the bivariate relationship between HIV risk attitudes and HIV risk behavior? 
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5. What is the bivariate relationship between treatment engagement and psychological 
dysfunction? 
6. Which combination of psychological problems (anxiety, depression, hostility) and 
treatment engagement (counseling rapport, treatment satisfaction, and treatment 
participation) best predict the amount of HIV risk behavior among methadone clients?  
7. What variables in the different stages of the ARRM Model best predict HIV risk 
behavior? 
8. Are clients with higher levels of psychological dysfunction less likely to engage in the 
drug treatment process, consequently, do they have higher levels of  HIV risk behavior 
than those with lower levels of psychological dysfunction?  
9. Are clients with higher levels of psychological dysfunction more likely to have lower 
HIV risk reduction attitudes, consequently,  do they have higher levels of  HIV risk 
behavior than those with lower levels of psychological dysfunction?  
Many of the research questions posed are based on the ARRM framework presented above.  
Accordingly, I focus in on the notion that drug-abusing populations have increased rates of 
psychological problems, which has been shown to impede the adoption of protective health 
behavior (Orr et al., 1994). As mentioned earlier, individual who have psychological problems 
may be less motivated to take action. This model explicitly states that individuals must be 
motivated in order to take action and, if not, the individual remains at risk. This model assumes 
that individuals have control over their behavior and that health action depends on their attitudes 
and beliefs, which may not be the case if an individual is suffering from a psychological 
problem.  Therefore, in the case of this model I am arguing that psychological problems 
(hostility, depression, and anxiety) may help in explaining HIV risk behavior among methadone 
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maintained clients. Specifically, I will explore whether clients with higher levels of psychiatric 
problems (psychological dysfunction) are less likely to engage or have lower levels of 
engagement in the protective health action (drug treatment engagement--methadone maintenance 
treatment) or view it as less meaningful. Consequently, does lower engagement put the client at a 
risk for higher levels of HIV risk behavior (continued drug use, unsafe sex, and unsafe needle 
practice). The conceptualized relationship between the central study variables are show in figure 
1. 
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Figure 1. Conceptual Model 
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4.0  METHODOLOGY 
4.1 PARTICIPANTS 
This study utilized a cross-sectional design to explore the relationship between psychological 
dysfunction, drug treatment engagement, HIV risk attitudes, and HIV risk behavior in a 
convenience sample of methadone maintenance clients from a large regional drug treatment 
facility located in Pittsburgh, PA. This treatment facility has been providing comprehensive care 
for chemically dependent people for 38 years. It offers a variety of services in two locations; 
however data were only collected from their main treatment site. The criteria for recruiting 
participants who were eligible for the study was as follows: 1) currently enrolled in methadone 
treatment for a minimum of 90 days 2) at least 18 years of age, 3) have injected illicit drugs or 
used non-injection drugs during the past 90 days, 4) able to read and speak English fluently.   
Participants completed a self-administered closed-ended questionnaire that measured the 
severity of psychological problems (depression, anxiety, and hostility), drug treatment 
engagement, HIV risk attitudes, HIV risk behavior, and demographic information. The design, 
sample, and selection criterion of the study was approved by the Institutional Review Board 
(IRB) of the University of Pittsburgh prior to the start date of the study (See Appendix A). I 
recruited 200 clients to analyze the relationship between psychological dysfunction and HIV risk 
behavior. 
28 
4.2 METHODS AND PROCEDURES FOR DATA COLLECTION 
After gaining approval from the IRB of the University of Pittsburgh, the survey was conducted at 
the methadone maintenance treatment facility. The study was conducted based on pre-arranged 
dates suggested by the treatment facility director. Study descriptions were sent to the HIV 
counselor at the treatment facility two weeks before the study began so that the counselor could 
inform the clients about the nature and purpose of the study before it took place. The study 
description emphasized participant confidentiality and the voluntary nature of the study. 
Additionally, the description explained the purpose of study, when the study would take place, 
and that the researcher needed to collect sensitive information regarding drug treatment 
experiences, drug use, and sexual activity. The study description informed the potential 
participants to contact the researcher if they were interested in more information pertaining to the 
study.  
The HIV counselor at the methadone treatment facility assisted in the recruitment process 
by passing out research study flyers and by assisting with the administration of the survey. 
Additionally, participants were recruited into the study by having several different designated 
days and times (approved by treatment facility) were I could be on site at the treatment facility 
for recruitment and administering the survey. This was done to avoid selection bias that may 
have occured if I was only on site during the times when the early clients arrived. The treatment 
facility administers services from 6:00 a.m. - 1:45 p.m. Monday through Saturday. 
The participants were informed that methadone treatment services were not connected to 
participating in the research study. All potential participants were screened for eligibility. If the 
individual was found to be eligible, they were given a verbal and written description of the study. 
After going over the description of the study and getting verbal consent, the self-administered 
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pencil-and-paper survey was conducted in a separate private location at the treatment facility. 
This was done to decrease the possibility that the researcher’s presence would coerce the 
respondent to answer in a more socially desirable or acceptable way and to allow for complete 
privacy due to the sensitive nature of the research questions. Additionally, participants were 
assessed to see if they were experiencing any confusion, stress, physical discomfort or worry 
from the survey procedure. I was also available to assist the participants to  interpret the 
questionnaire and to  assure participants that their confidentiality would not be compromised. 
The benefit to utilizing a pencil-and-paper survey is that the research participants were 
able to complete the survey at their own convenience, giving them time to consider their 
responses. Participants were also afforded complete confidentiality-offering them the greatest 
opportunity to be fully truthful in their responses (when an interviewer is present, research 
participants may not disclose their true feelings if the topic is sensitive). The survey specifically 
asked participants to be open and honest with their responses due to the highly personal nature of 
questions. Participants were reminded that the survey was completely confidential and that their 
names or client ID numbers were not to be placed on survey in order to protect their 
confidentiality. The complete questionnaire and recruitment letter is included in Appendix B. 
After successful completion of the survey each participant was given $5.00 for his or her 
participation. This incentive was noted in the written description given to the participant at the 
beginning of the survey. 
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4.3 STUDY VARIABLES AND MEASUREMENT 
The study adapted measures from various previous studies. The Texas Christian University 
(TCU) Self-Rating Form (TCU/SRF; Simpson 1992); The Texas Christian University (TCU) 
Client Evaluation of Self and Treatment (TCU CEST; Joe et al., 2002); The HIV Risk-Taking 
Behavior Scale (HRBS; Darke et al., 1991); The HIV/AIDS Risk Assessment Form (ARA; 
Simpson, 1998); AIDS Risk Reduction Measure (ARRM; Longshore et al., 1998) and a 
demographic measure. 
4.3.1 Texas Christian University (TCU) Self-Rating Form  
The Texas Christian University (TCU) Self-Rating Form (Psychological and Social Functioning 
Domains) was used to assess three aspects psychological functioning: depression, anxiety, and 
hostility (independent variables). Psychological functioning is an important consideration in 
drug abuse intervention strategies (Simpson, 1992). Psychological functioning has been found to 
be related to coping with health threats (Ostrowe et al., 1989; Joe et al., 1991).  Poor social 
functioning has also been found to relate negatively to drug treatment engagement and retention 
in drug treatment (Joe et al., 1999; Broome et al., 1999).  
The Depression Scale of the TCU/SRF consists of six items that are conceptually similar 
to many items of the Beck Depression Inventory (Beck & Steer, 1987) and the Symptom 
Checklist-90 (SCL-90) (Derogatis et al., 1973). The Depression scale of TCU/SRF has had a 
history of a relatively high alpha reliability coefficient of .87 (Joe et al., 2002; Myers et al., 1991; 
Simpson et al., 1992; Simpson, 1991; Simpson et al., 1993). In addition, the TCU/SRF 
depression scale score has been found to be highly correlated with the SCL-90 depression scale 
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(r=.81, Myers et al., 1991) and the Beck Depression Inventory (r=.75, Simpson et al., 1992). 
Preliminary evidence has also found a test-retest reliability coefficient of .86 (Simpson, 1991). 
Item-total correlations have also been acceptable (Joe et al., 1991).   
The Anxiety Scale of the TCU/SRF consists of seven items and is similar conceptually to 
those of the Hamilton Anxiety Scale and the Anxiety Scale from the SCL-90. Prior research with 
the TCU/SRF Anxiety Scale has demonstrated good psychometric characteristics. For example, 
one study found a reliability alpha coefficient of .83 for this particular scale (Simpson et al., 
1993). In addition, a test-retest reliability coefficient of .84 was found with a sample of 44 
substance abusing probationers tested 8-10 days apart (Simpson, 1991). In addition, the 
TCU/SRF Anxiety Scale score has been found to be highly correlated with the SCL-90 anxiety 
scale score (r=.74, Myers et al., 1991). Finally, all TCU/SRF Anxiety Scale items have 
consistently demonstrated acceptable item-total correlations and individual item distributions 
have been relatively normal. 
The Hostility Scale of the TCU/SRF has eight items and has continually had good 
psychometric properties across multiple studies. For example, coefficient alpha reliabilities have 
been found to be above .75, and a principal components analysis confirmed its unidimensionality 
(Simpson & Joe, 1993; Simpson, 1991). A test-retest reliability coefficient of .88 was found with 
a sample of 44 substance abusing probationers tested 8-10 days apart (Simpson, 1991). In 
addition, the TCU/SRF hostility scale has been found to be correlated with the SCL-90 hostility 
scale score (r=. 61, Myers et al., 1991).  
All of the scales mentioned above (depression, anxiety, hostility) are rated on a 5-point 
scale from 1 = “Strongly Disagree” to 5 = “Strongly Agree”. Scores for each scale are obtained 
by summing the responses to its set of items (after reverse scoring where appropriate), dividing 
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the sum by number of items included (yielding and average) and multiplying the total by10 in 
order to rescale final scores to get a range between 10 and 50 (e.g., an average response of 2.6 
for a scale would become 26). Higher scores indicate higher level of psychological dysfunction 
on the particular psychological problem being measured. This instrument can also yield an 
overall score of psychological dysfunction (Simpson, 1991). 
4.3.2 HIV Risk-Taking Behavior Scale/ HIV/AIDS Risk Assessment  
Items taken from the HIV Risk-taking Behavior Scale, the HIV/AIDS Risk Assessment, and 
items that I created were used to assess HIV sexual and drug risk behavior (dependent variable) 
among the research participants. I asked participants to respond to thirty-nine items that 
measured both drug use and sex risk in the past 3 months. This measure is divided into three 
subscales: injection drug use (7-items), non-injection drug use (15-items that I added), and 
sexual behavior (17-items -2 added that I added). The Texas Christian University HIV/AIDS 
Risk Assessment developed by Simpson, 1997 (alpha coefficient >.70) and from the HIV Risk-
taking Behavior Scale (alpha coefficient =. 70; test-retest reliability (one week) = .86 developed 
by Darke et al. in 1991.  The new scale was created by combining items from both scales and by 
including additional items of risk that are characteristic of this population (i.e., frequency of 
being diagnosed with an sexually transmitted disease, frequency of non-injection drug use, and 
where individuals typically get their needles). In addition, I modified the scoring of the 
instrument so that all items were measured and scored in the same metric. From a pilot study 
conducted by the researcher in 2005 with 100 methadone clients the new scale yielded the 
following coefficient alphas: injection drug use subscale (7-items), non-injection drug use (15-
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items) and the sexual behavior subscale (17-items) had coefficient alphas of .70, .75, and .70 
respectively with the overall scale having a coefficient alpha of .80.  
To obtain a score for this scale, each subscale was sum scored. This scale provides 4 
scores: a total score indicating overall level of HIV risk behavior; an injection drug use score 
indicating the level of risk due to injection drug risk, a non-injection drug use score indicating 
the level of risk due to non-injection drug use behavior, and a sexual behavior score indicating 
the level of risk associated with unsafe sexual practices. In all cases the higher the score, the 
greater the risk the participant has of contracting/transmitting the HIV virus. Behaviors are rated 
on a 6-point scale according to number of times a behavior occurred, number of people involved 
in the behavior, and according to the frequency of occurrence (0= “No times or None ” to 5= 
“More than 10 people or more than 10 times ”).  The specific wording of the items are as 
follows: “How many times have you injected drugs in the last 3 months?” (Injection Drug Use 
Behavior), “Not counting the drugs you injected, how many times did you use crack cocaine in 
the last 3 months?” (Non-Injection Drug Use Behavior), and “How many times did you have sex 
without a condom with someone who shoots drugs with needles in the last 3 months?” (Sexual 
Behavior).  
4.3.3 AIDS Risk Reduction Measure  
Attitudes toward HIV/AIDS risk behavior were assessed utilizing the AIDS Risk Reduction 
Measure.  The ARRM is comprised of 40-items and assesses participant attitudes and concerns 
about HIV/AIDS and the ways in which individuals can become infected with HIV/AIDS. These 
items are relevant to the psychosocial constructs of the ARRM.  The following constructs were 
assessed: AIDS knowledge (10-items), perceived susceptibility (2- items), perceived infection 
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risk (2-items), response efficacy (4-items), perceived self-efficacy (7- items), intended risk 
reduction (5-items), motivating factors- fear (1-item), peer norms (6-items) informational cues to 
action (3-items) and interpersonal cues to action (2-items). The specific wording of the items are 
as follows:  “HIV only affects gay men”  (HIV knowledge), “I never do anything that could give 
me HIV” (perceived susceptibility), “ I am not worried about passing HIV to others” (perceived 
risk of infection), “Using condoms can reduce the chance of getting HIV” (response efficacy) , 
“I’d rather get dope sick (withdrawal) than share works” (perceived self-efficacy), “in the year 
ahead I will share works” (intended risk reduction), “HIV/AIDS is the most frightening disease I 
know (fear), “My friends are not using condoms when they have sex” (peer norms), “Have you 
ever had face-to-face HIV education in the past year?” (informational cues), “How many people 
do you know personally who have been infected with HIV/AIDS?” (interpersonal cues).  Using a 
Likert-type scale ranging from (1) strongly agree to (4) strongly disagree items are summed 
scored with higher scores indicating a higher level of the construct being measured.  For 
informational and interpersonal cues items were scored with yes or no responses of number of 
friends/family known to be HIV positive or have died of AIDS. Higher scores indicate stronger 
cues to action. 
4.3.4 Client Evaluation of Self and Treatment  
For the purpose of this study, drug treatment engagement is defined as a process of developing a 
trusting relationship between a counselor and client. It is a process whereby the counselor 
establishes regular contact and a helpful relationship with a client in order to foster recovery 
from drugs and alcohol (Simpson, 2004). In addition, drug treatment engagement is measured 
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primarily by program participation and the formation of a therapeutic relationship with an 
assigned counselor (counseling rapport).  
Drug treatment engagement was measured using the TCU Institute of Behavioral 
Research Client Evaluation of Self and Treatment-Therapeutic Engagement Domains (CEST; 
Joe et al., 2002). The Therapeutic Engagement Domain of CEST measures drug treatment 
performance in relationship to drug treatment engagement. This 33-item scale is intended to 
measure 3 subscales related to: (1) treatment satisfaction (7-items), (2) counseling rapport (14-
items), and (3) treatment participation (12-items). Item examples are: “I am satisfied with this 
program” (treatment satisfaction), “I trust my counselor” (counseling rapport), and “I am 
following my counselor’s guidance” (treatment participation). Using a Likert-type scale items 
are rated on a 5-point Likert type scale ranging from 1= “Strongly Disagree” to 5= “Strongly 
Agree” on how participants feel about treatment progress, rapport and relationship with their 
primary counselor, treatment satisfaction, and participation in the therapeutic process.  
Scores for each of the subscales are obtained by summing responses to the set of items 
(after reversing scores on reflected items by subtracting the item response from “6”), dividing the 
sum by number of items included (yielding an average) and multiplying by 10 in order to rescale 
final scores so they range from 10 to 50 (e.g., an average response of 2.6 for a scale becomes a 
score of “26”) (TCU, 2005). Higher scores indicate more confidence in the particular factor 
being measured. These scales have been shown to be reliable and valid with a national sample of 
over 1500 clients from 87 programs with subscale coefficient alphas ranging from .86 to .96 (Joe 
et al., 2002).  From a pilot study that I conducted in 2005 with 100 methadone clients the CEST 
(Therapeutic Engagement Domain) yielded the following coefficient alphas: treatment 
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satisfaction α= .79, counseling rapport α= .93, and treatment participation α =.89. The scores 
were normally distributed across this measure.  
4.3.5 Control Variables and Demographic Information 
In addition to the central study variables, a number of other variables, related to both the 
independent and dependent variables, were controlled. The following items were included as 
control variables in the study: current age, sex, race/ethnicity, and length of time in current 
treatment setting. Other demographic information was collected for descriptive purposes: marital 
status, level of education, current employment status, financial status, household composition, 
past drug treatment participation, and number of times in drug treatment. 
4.4 DATA ANALYSIS STRATEGY 
I used SPSS 11.5 statistical software to analyze the data. All data were first entered into a 
codebook followed by the naming and coding of each variable. To assist in the data cleaning 
process I examined frequency distributions and percentages for all variables. Additionally, 
measures of central tendency, dispersion, and distribution were obtained for the central study 
variables.  
Descriptive statistics/analyses were conducted to describe the sample’s demographic and 
key study variables. Specifically, descriptive statistics were utilized to answer the following 
question: 
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1. How prevalent are psychological disorders (anxiety, depression, and hostility) and HIV 
risk behavior among an urban of sample of methadone clients?  
Bivariate correlations statistics were used to assess the relationships among the study variables. 
Specifically, I calculated Pearson’s correlations (p=.05) to answer the following questions:  
2. What is the bivariate relationship between level of psychological dysfunction (anxiety, 
hostility, and depression) and level of HIV risk behavior?  
3. What is the bivariate relationship between level treatment engagement and HIV risk 
behavior?  
4. What is the bivariate relationship between HIV risk attitudes and HIV risk behavior? 
5. What is the bivariate relationship between treatment engagement and psychological 
dysfunction? 
Multiple regression analyses were used to answer the following question: 
6. Which combination of psychological problems (anxiety, depression, hostility) and 
treatment engagement (counseling rapport, treatment satisfaction, and treatment 
participation) best predict the amount of HIV risk behavior among methadone clients?  
7. What variables in the different stages of the ARRM Model best predict HIV risk 
behavior? 
8. Are clients with higher levels of psychological dysfunction less likely to engage in the 
treatment process, consequently, do they have higher levels of  HIV risk behavior than 
those with lower levels of psychological dysfunction?  
9. Are clients with higher levels of psychological dysfunction more likely to have lower 
HIV risk reduction attitudes, consequently,  do they have higher levels of  HIV risk 
behavior than those with lower levels of psychological dysfunction? 
 
38 
To produce the best combination of predictors of the dependent variable, I used standard 
multiple regression along with a sequential regression model in which I selected independent 
variables, one at a time, by their ability to account for the most variance in the dependent 
variable. As each independent variable was entered into the group of predictors, the relationship 
between the group of predictors and the dependent variable was reassessed. When no variables 
were left that explained a significant amount of variance in the dependent variable, the regression 
model was considered complete. I used this strategy to predict the best combination of 
independent variables for each subscale of the dependent variable (injection drug use, non-
injection drug use, and sexual risk behavior) and the overall measure of HIV risk behavior.  
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                     5.0  RESULTS 
This chapter presents the findings from the analyses of data collected on 200 methadone 
treatment clients in Pittsburgh, PA. These clients were all enrolled in treatment at least 90 days 
prior to the start date of data collection at their treatment facility. The first section presents a 
summary of the demographic characteristics of the sample, followed by a presentation of 
bivariate and multivariate findings related to the nine research questions that guided the study.   
5.1 DESCRIPTIVE INFORMATION 
5.1.1 Background Characteristics 
Table 1 shows the demographic characteristics of the 200 respondents. The age of the 
participants ranged from 20 to 69. The mean age was 42.55 years (SD=11.78). Of the 200 
participants, 41.5% (83) were female and 58.5% (117) were male. Consistent with the population 
of the treatment center, more than half of the participants were Caucasian (117; 58.5%), 39.5% 
were African American (79), 2% were Hispanic (4), and 0.5% (1) of the participants reported 
other to describe themselves racially.  
About 27% (54) of participants were currently married (legally married and common law 
marriage), 47.5% (95) were never married, 21% (42) either separated (10.5 %) or divorced 
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(10.5%), and 4.5% (9) were widowed. About 40% (79) of the participants reported living with 
family or other relatives, 28.5% (57) reported living with a boyfriend/ girlfriend, 23.5% (47) 
reported living alone, and 7% (14) reported that they were either homeless (2.5%), living with a 
group of friends/friend (4%), or hospitalized or living in a rehabilitation center during the past 90 
days prior to the study (0.5%). More than half 56% (112) finished high school, 24.5% (49) had 
some college experience, 5.5% (11) completed college, and 3% (6) had completed a graduate or 
professional degree. Almost one-third (53) of the sample had some type of legal problem (i.e., 
probation, parole, awaiting sentence, warrant, or pending case). 
Of the 200 participants, 27.5% (55) reported that they were employed and 72.5% (145) 
reported being unemployed. Only 166 participants reported their income. Nearly half (49.4%) of 
the participants reported income under $8000, while 12% reported no income for the prior year. 
The mean income for this sample population was $11,576 (SD=$12,760). When participants 
were ask what their sources of support were for the prior year, 56.5% (113) reported welfare, 
public assistance, or disability, 35% (70) reported job, 17.5% (35) family/friends 16.5% (33) 
mate/spouse, 15% (30) selling drugs/other illegal activities, 11.5% (23) unemployment, 5% (10) 
prostitution and 1.5 % (3) retirement income. 
Of the 200 participants in the study, 95% (190) had attended outpatient drug-free 
treatment prior to attending their current treatment program. Other types of treatment programs 
attended by participants were partial hospitalization 25% (50), inpatient drug treatment 44.5% 
(89), residential drug treatment 34% (68), and detoxification 58% (116). The average length of 
time in current drug treatment program for this sample was 33.74 months (SD= 33.78). About 
68% (136) of the sample had between 1-4 treatment experiences prior to attending treatment at 
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their current treatment program, while 16.5% (33) had 5 or more other treatment experiences. 
Fifteen percent (31) of the sample had no prior treatment experience. 
 
Table 1.  Demographic Characteristics of Participants (N=200) 
Variables Frequency Percent M SD 
Age 198 
Min. =20 
Max.=69 
 42.55 11.78 
Gender 
   Male 
   Female 
 
117 
  83 
 
58.5 
41.5 
  
Race 
   White 
   Black 
   Hispanic/Other 
 
116 
  79 
    5 
 
58.0 
39.5 
  2.5 
  
Marital Status 
   Never Married 
   Legal Married 
   Common Law 
   Divorce/Sep. 
   Widowed 
 
95 
34 
20 
42 
  9 
 
47.5 
17.0 
10.0 
21.0 
  4.5 
  
Living Arrangements 
   Family/other relat. 
   Boyfriend/Girlfriend 
   Live Alone 
   Homeless/other 
 
79 
57 
47 
14 
 
39.5 
28.5 
23.5 
  7.0 
  
Education 
   Less than 12th grade 
   High school 
   Some Collete 
   College 
   Graduate 
 
  22 
112 
  47 
  11 
    6 
 
11.0 
56.0 
23.5 
  5.5 
  3.0 
  
Employment Status 
   Employed 
   Not employed 
 
  55 
145 
 
27.5 
72.5 
  
Income 166  $11,576 $12,761 
Legal Status 
   None 
   Probation 
   Case Pending 
   Awaiting trial/other 
 
139 
  32 
  13 
    8 
 
69.5 
16.0 
  6.5 
  8.0 
 
 
 
 
 
 
 
 
 
 
Length of time in Tx 200  33.74 33.78 
Sources of fin. Support 
   Welfare/Disability 
   Job/unemployment 
   Mate/Spouse 
   Family/Friends 
   Illegal Activities 
 
113 
  93 
  33 
  35 
  51 
 
56.5 
46.5 
16.5 
17.5 
25.5 
  
Note:  There is missing information for some variables so totals are not all 200. 
Dichotomous variables were coded as follow:  Gender: 1 = female, 2 = male; Employment: 1 = 
not employed, 2 = employed. 
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5.2 DESCRIPTIVE AND PSYCHOMETRIC FINDINGS OF STUDY VARIABLES 
The data from this sample were evaluated for accuracy of entry, normality of distribution, and 
outliers. Values for all of the study variables were verified to make certain that they fell within 
the possible range upon which the measures were based. Skewness and kurtosis of each measure 
were reviewed to detect whether they were in an acceptable range of ± 1.0. In this section, the 
mean, standard deviation, skewness, and kurtosis of the measures are reported. These data are 
summarized in Table 2.  
 
Table 2.  Mean, Standard Deviation, Skewness, and Kurtosis of the Instruments 
Instruments Mean SD Skewness Kurtosis 
Psychologic Dys.   80.5 21.57     .01     .05 
Anxiety   31.33 10.36   -.32   -.83 
Hostility   23.43 10.12     .43   -.58 
Depression   25.75   8.89     .24   -.57 
Treatment Engage. 108.98 23.19   -.54    .35 
Treatment sat.   34.80   9.55   -.48   -.21 
Counseling rapport   36.90   8.89   -.60    .23 
Treatment participation   37.28   8.53   -.98  1.05 
HIV Risk Behavior   36.04 23.00    1.23/.41*  1.72/-03* 
Sex Risk   15.06 12.14 -1.01 -1.37 
Non-Injection   15.81   9.46   -.85    .49 
Injection Risk     5.17   5.85  1.08   -.78 
HIV Knowledge     7.41  1.84  -.74    .18 
Informational Cues     2.35    .84       -1.30  1.18 
Interpersonal Cues     1.17    .90  -.34 -1.67 
Perceived Susp.     5.43  1.43  -.29    .08 
Perceived Risk     5.10  1.46  -.17   -.21 
Response Efficacy   11.95  2.12  -.11   -.19 
Self-Efficacy   19.81  3.24   .41    .14 
Intended Risk Red.   14.23  2.78   .10   -.36 
Peer Norms   15.59  2.51         -.90    .07 
Fear     3.31    .80   .44  1.04 
*HIV risk behavior was transformed utilizing the square root method. 
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5.2.1 Psychological Dysfunction 
Twenty-one items from the psychological/social functioning domains of the CEST were used to 
assess psychological dysfunction which is intended to measure 3 psycho-social subscales related 
to :(1) depression (6 items), (2) anxiety (7 items), and (3) hostility (8-items). Items were rated on 
a 5-point Likert type scale ranging from 1= “Strongly Disagree” to 5= “Strongly Agree” 
pertaining to symptoms relative to psychological or social problem. Higher scores indicate 
higher level of psychological dysfunction on the particular psychological problem being 
measured (Simpson, 2001). 
5.2.1.1 Depression 
The measure for depression consisted of six items that are conceptually similar to many items of 
the Beck Depression Inventory (Beck & Steer, 1987) and the Symptom Checklist-90 (SCL-90) 
(Derogatis et al., 1973). Scores for this scale were rated on a 5-point scale from 1 = “Strongly 
Disagree” to 5 = “Strongly Agree”. Higher scores indicate higher level of psychological 
dysfunction on the depression problem being measured. The mean score in this sample was 25.8 
(SD=8.89), suggesting that participants experienced a moderately high level of depressive 
symptoms/psychological dysfunction during the 90 days prior to the research study. The two 
highest rated items on the depression scale as identified by participants were, “I feel extra tired 
or run down” (M=3.18) and “I worry or brood a lot” (M=3.14). The two lowest rating on the 
depression scale were, “I feel interested in life” (M=2.32) and “I feel hopeless about the future” 
(M=2.72). Almost half (43%) of the participants stated that they feel sad or depressed.  
On the CEST (depression scale), those scoring 30 or higher is considered a problem 
behavior. The normative mean for drug and alcohol clients is 25.7 (SD=8.0) (Simpson, 2001). In 
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the present study, the mean depression score was 25.8, a value consistent with the national 
average score, suggesting that this sample is experiencing the same level of depressive symptoms 
when compared to other drug and alcohol clients around the United States. Over 75% of the 
sample experienced moderate to high depressive symptoms. The complete distribution of 
individual items for the depression subscale can be found in Appendix D, Table 10. 
5.2.1.2 Anxiety 
The measure for anxiety consisted of seven items that are similar conceptually to those of the 
Hamilton Anxiety Scale and the Anxiety subscale from the SCL-90. Scores for this scale were 
rated on a 5-point scale from 1 = “Strongly Disagree” to 5 = “Strongly Agree”. Higher scores 
indicate a higher level of psychological dysfunction on the particular psychological problem 
being measured. The mean score in this sample was 31.3 (SD=10.36), suggesting that 
participants experienced a high level of anxiety symptoms during the 90 days prior to the 
research study. The two highest rated items on the anxiety scale as identified by participants 
were, “I have trouble sleeping” (M=3.25) and “I feel anxious and nervous” (M=3.12). The two 
lowest rating on the anxiety scale were, “I feel afraid of certain things” (M=2.66) and “I have 
trouble sitting still for long periods of time” (M=3.01). Almost half (46.5%) of the participants 
stated that they have trouble concentrating or remembering things.  
On the CEST (anxiety scale), those scoring 30 or higher are considered to be 
experiencing problems due to the particular problem being measured (anxiety). The normative 
mean for drug and alcohol clients is 28.1 (SD=8.4) (Simpson, 2001). In the present study, the 
mean anxiety score was 31.3, a value higher than the national average score, suggesting that this 
sample is experiencing more symptoms as it relates to anxiety when compare to other drug and 
alcohol clients around the United States. Over 70% of the sample experienced moderate to high 
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anxiety symptoms. The complete distribution of individual items for the anxiety subscale can be 
found in Appendix D, Table 11. 
5.2.1.3 Hostility 
The measure for hostility consisted of eight items that are similar conceptually to those of the 
hostility subscale from the SCL-90. Scores for this scale were rated on a 5-point scale from 1 = 
“Strongly Disagree” to 5 = “Strongly Agree”. Higher scores also indicate higher level of 
psychological dysfunction on the particular psychological problem being measured. The mean 
score in this sample was 23.4 (SD=10.12), suggesting that participants experienced a moderate 
level of hostility symptoms during the 90 days prior to the research study. The two highest rated 
items on the hostility scale as identified by participants were, “I feel a lot of anger inside of me” 
(M=2.76) and “I have a hot temper” (M=3.14). The two lowest rated items on the hostility scale 
were, “I like others to feel afraid of me” (M=1.97) and “My temper gets me into fights or other 
trouble” (M=2.25). Almost one-third (30%) of the participants stated that they have carried a 
weapon.  
On the CEST (hostility scale), those scoring 30 or higher are considered to experiencing 
problems due to the particular construct being measured. The normative mean for drug and 
alcohol clients is 24.6 (SD=8.0) (Simpson, 2001). In the present study, the mean hostility score 
was 23.4. Over 50% of the sample experienced moderate to high hostility symptoms The 
complete distribution of individual items for the hostility subscale can be found in Appendix D, 
Table 12. 
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5.2.1.4 Overall Psychological Dysfunction 
The measure for overall psychological dysfunction was comprised of scores from the depression, 
anxiety, and hostility measures and summing those scores in order to yield an overall score of 
psychological dysfunction. The mean score in this sample was 80.50 (SD=21.57), suggesting 
that participants experienced a moderate level of psychological dysfunction during the 90 days 
prior to the research study. About 60% of the participants experienced moderate to high levels of 
psychological dysfunction 
5.2.2 Treatment Engagement 
The 33-item therapeutic engagement domain of the CEST was used to assess treatment 
engagement which is intended to measure 3 treatment engagement subscales related to :(1) 
treatment satisfaction (7 items), (2) counseling rapport (14 items), and (3) treatment participation 
(12-items). Items were rated on a 5-point Likert type scale ranging from 1= “Strongly Disagree” 
to 5= “Strongly Agree” on how participants feel about treatment progress, rapport and 
relationship with primary counselor, and treatment satisfaction and participation in the 
therapeutic process. Higher scores indicate more confidence in the particular factor being 
measured. Scores above 40 are considered high treatment scores. 
5.2.2.1 Treatment Satisfaction 
The treatment satisfaction scores in this study ranged from 10 to 50, with higher scores 
indicating that participants are more satisfied with the treatment that they are receiving from their 
treatment program. The average treatment satisfaction score for this sample was 34.8 (SD=9.55), 
which indicates that participants are reasonably satisfied with the treatment that they received 
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from their treatment program. The two items that participants identified as most satisfying about 
their treatment program were, “This program expects me to learn responsibility and discipline” 
(M=3.90) and “I can get plenty of personal counseling at this program” (M=3.79). The two items 
that participants identified as least satisfying were, “This program location is convenient for me” 
(M=3.29) and “I am satisfied with this program” (M=3.49).  
On the CEST (treatment satisfaction scale), the normative mean for drug and alcohol 
clients is 37.8 (SD=6.9) (Simpson, 2001). In the present study, the mean treatment satisfaction 
score was 34.8. The complete distribution of individual items for the treatment satisfaction 
subscale can be found in Appendix D, Table 13. 
5.2.2.2 Counseling Rapport 
The counseling rapport scores in this study ranged from 10 to 50, with higher scores indicating 
that participants have a more solid formation of a therapeutic relationship with his or her 
assigned counselor. The average counseling rapport score for this sample was 36.9 (SD=8.89), 
which indicates that participants were moderately engaged in the therapeutic relationship with 
their counselors. Approximately 80% of the participants answered that their counselor allowed 
them to give feedback in their treatment plan. In addition, 75% of the participants reported that 
their treatment plans were reasonable and that talking to their counselors was easy (71.5%). 
On the CEST (counseling rapport scale), the normative mean for drug and alcohol clients 
is 39.6 (SD=6.5) (Simpson, 2001). In the present study, the mean counseling rapport score was 
36.9 which is slightly lower than the national average score, but still suggesting that this sample  
experienced a moderately high level of satisfaction within his or her counseling relationship. The 
complete distribution of individual items for the counseling rapport subscale can be found in 
Appendix D, Table 14. 
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5.2.2.3 Treatment Participation 
The treatment participation scores ranged from 10 to 50, with higher scores indicating that 
participants have more treatment participation.  The average treatment participation score for this 
sample was 37.3 (SD=8.53), which indicates that participants were highly involved in their drug 
treatment experience. The two highest rating for treatment participation identified by participants 
were, “I have made progress with my drug/alcohol problem” (M=3.99) and “I have stopped or 
greatly reduced my use while in this program” (M=3.97). The two lowest ratings for treatment 
participation that respondents identified were, “I feel comfortable giving negative feedback 
during counseling” (M=3.52) and “I have made progress with my emotional or psychological 
issues” (M=3.55).  
On the CEST (treatment participation scale), the normative mean for drug and alcohol 
clients is 40.6 (SD=5.2) (Simpson, 2001). In the present study, the mean treatment satisfaction 
score was 37.3 which is lower than national average score, suggesting that this sample along 
with the national sample of drug and alcohol clients are  experiencing a moderately high  to high 
rates of  treatment participation. The complete distribution of individual items for the treatment 
participation subscale can be found in Appendix D, Table 15. 
5.2.2.4 Overall Treatment Engagement 
The measure of overall treatment engagement was comprised by summing the scores from the 
treatment satisfaction, counseling rapport, and treatment participation subscales of the 
therapeutic domain of the CEST in order to yield an overall score of treatment engagement. The 
mean score in this sample was 109.0 (SD=23.19), suggesting that participant were moderately 
highly engaged in the drug treatment process during the 90 days prior to the research study. 
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5.2.3 HIV Risk Behavior 
The measure for HIV risk behavior consisted of 39 items, which were divided into three 
subscales: injection drug use (7 items), non-injection drug use (15 items), and sexual behavior 
(17 items). Scores for these subscale were obtained by summing items that were rated on a 6-
point scale ranging from 0= “No times or None” to 5= “More than 10 people or 10 times”. This 
measure provides 4 scores: an injection drug use, a non-injection drug use, a sexual behavior, 
and a total score indicating the participants overall level of HIV risk behavior. In call cases the 
higher the score, the greater the risk the participant has of contracting/transmitting the HIV virus. 
5.2.3.1 Injection Drug Use Risk 
The measure for injection drug use risk consisted of six items that were rated on a 6-point scale 
ranging from 0 to 5. Scores in this study ranged from 0 to 27, with higher scores indicating more 
risk as it relates to injection drug use.  Almost half (45.5%) of the participants reported injecting 
drugs once a week or more during the past 3 months. Participants were asked where they got 
their needle that last time they injected drugs, 42.5% reported that they got their needle from the 
pharmacy/needle exchange/hospital, 19% from a diabetic family member or friend, 16.5% from 
drug-using friends, 8.5% from the streets (someone sold it to them), and 5% got needles from a 
shooting gallery (2.5%) or a friend known to be HIV+ (2.5%).  The average injection drug use 
risk score for this sample was 5.17 (SD=5.85), which indicates that participants were engaging in 
less risky behavior as it relates to injection drug use. The distribution of individual items for the 
injection drug use subscale can be found in Appendix D, Table 16. 
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5.2.3.2 Non-Injection Drug Use Risk   
The non-injection drug use risk measure consisted of 13 items that was rated on 6-point scale 
ranging from 0 to 5.  Scores in this study ranged from 0 to 48, with higher scores indicating more 
risk as it relates to injection drug use.  Almost all (97%) of the participants reported that they 
smoked, snorted, sniffed, or took any drug orally during the 3-month period prior to the study. 
Drugs most commonly used by participants were: alcohol (54%), xanax/klonopin/valium 
(prescription medication) (50%), marijuana (45%), heroin (44%), and crack cocaine (43%).  
Forty- two percent (42%) of the participants reported that they had been drunk one or more times 
during the 3 months period prior to the study.  The average non-injection drug use risk score for 
this sample was 15.81 (SD=9.46), which indicates that participants were engaging in moderate 
levels of risky behavior as it relates to non-injection drug use. The distribution of individual 
items for this scale can be found in Appendix D, Table 17. 
5.2.3.3 Sexual Behavior Risk  
The sex risk measure consisted of 13 items that was rated on 6-point scale ranging from 0 to 5.  
The sexual behavior risk scores in this study ranged from 0 to 61, with higher scores indicating 
more risk as it relates to sexual risk behavior. Approximately 76% of the participants reported 
that they had sex during the 3-month period prior to the study. Of those that had sex, 22.5% (45) 
had two or more sex partners, 38% (76) rarely/never used condoms with regular partner, and 
16% rarely/never use condoms with causal sex partner. Sexual practices utilized among this 
sample were: vaginal sex (61%), oral sex (69.5%), and anal sex (18.5%) The average sexual 
behavior risk score for this sample was 15.06 (SD=12.14), which indicates that participants were 
engaging in moderate levels of risky behavior as it relates to sex. A common risk factor for 
contracting HIV is prior infection with a sexually transmitted disease (STD). This study’s 
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findings indicate that 46.5% of the sample had been in infected one or more times with a STD.  
Ten percent of the sample reported that they had test positive for HIV. The distribution of 
individual items for the sexual behavior subscale can be found in Appendix D, Table 18. 
5.2.3.4 Overall HIV Risk Behavior 
The overall HIV risk behavior scores in this study ranged from 4 to 120, with higher scores 
indicating more risk as it relates to injection drug use, non-injection drug use, and sexual risk 
behavior. The measure of overall HIV risk behavior was comprised by summing the scores from 
the injection drug use, non-injection drug use, and sexual behavior risk subscales of the HIV 
Risk Behavior Scale in order to yield an overall score of HIV risk behavior. The mean score in 
this sample was 36.04 (SD=23.00), suggesting that participants were engaging in significant 
amounts of HIV risk behavior during the 90 days prior to the research study.  
5.2.4 AIDS Risk Reduction Attitudes 
The measure for HIV risk reduction attitudes consisted of 40 items which are consistent with the 
constructs of the AIDS Risk Reduction Model, a three-stage model, that examine participant 
attitudes and concerns about HIV/AIDS and the ways in which individuals can become infected 
with HIV/AIDS.  The following constructs were assessed: AIDS knowledge, perceived 
susceptibility, perceived infection risk, response efficacy, perceived self-efficacy, intended risk 
reduction, motivating factors- fear, peer norms, informational cues to action, and interpersonal 
cues to action. 
Using a Likert- type scale ranging from (1) strongly agree to (4) strongly disagree items 
are summed scored with higher scores indicating more of the construct being measured.  For 
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informational and interpersonal cues, items were scored with yes or no responses of number of 
friends/family known to be HIV positive or have died of AIDS. Higher scores indicate stronger 
cues action. 
5.2.4.1   HIV Knowledge 
The measure for HIV knowledge consisted of ten items that were rated on 4- point scale ranging 
(1) strongly agree to (4) strongly disagree. The HIV knowledge scores in this study ranged from 
1 to 10, with higher scores indicating that participants have more HIV knowledge. The average 
HIV knowledge score for this sample was 7.41 (SD=1.84), which indicates that participants have 
average knowledge about the risk factors pertaining to HIV/AIDS.   
On the ARRM (HIV knowledge scale), the normative mean for similar drug and alcohol 
clients (N=294) enrolled in methadone treatment is 7.75 (SD=3.5) (Longshore et al., 2004). In 
the present study, the mean HIV knowledge score was 7.41, which is slightly lower than the 
score of the comparative sample, but suggesting that this sample has roughly the same HIV 
knowledge as other clients enrolled in methadone treatment. The distribution of individual items 
for the HIV Knowledge Scale can be found in Appendix D, Table 19. 
5.2.4.2   Perceived Susceptibility 
The measure for perceived susceptibility consisted of two items that were rated on 4- point scale 
ranging (1) strongly agree to (4) strongly disagree. The perceived susceptibility scores in this 
study ranged from 2 to 8, with higher scores indicating that participants have more perceived 
susceptibility to contracting HIV. The average perceived susceptibility score for this sample was 
5.43 (SD=1.43), which indicates that participants believed that they were reasonably susceptible 
to contracting HIV/AIDS.  
53 
On the ARRM (perceived susceptibility scale), the normative mean for drug and alcohol 
clients in methadone treatment is 2.75 (SD=.63) (Longshore et al., 2004). In the present study, 
the mean perceived susceptibility score was 5.43 which is higher than the mean score of the 
comparative sample, suggesting that this sample perceives that they are more susceptible to 
contracting HIV than other clients enrolled in methadone treatment. The distribution of 
individual items for the perceived susceptibility scale can be found in Appendix D, Table 20. 
5.2.4.3   Perceived Risk of Infection 
The measure for perceive risk of infection consisted of two items that were rated on 4- point 
scale ranging (1) strongly agree to (4) strongly disagree. The perceived risk scores in this study 
ranged from 2 to 8, with higher scores indicating that participants perceive themselves to be at a 
higher risk of contracting HIV/AIDS. In this study, the average perceived risk of infection score 
was 5.09 (SD=1.46), which indicates that participants believed that they were at a moderate risk 
of being infected with HIV. The distribution of individual items for the perceived risk of 
infection scale can be found in Appendix D, Table 20. 
5.2.4.4   Perceived Response Efficacy  
The measure for perceived response efficacy consisted of four items that were rated on 4- point 
scale ranging (1) strongly agree to (4) strongly disagree. The response efficacy scores in this 
study ranged from 6 to 16, with higher scores indicating that participants had more positive 
beliefs about the efficacy of sexual and drug risk reduction strategies or higher perceived 
response efficacy. In this study, the average perceived risk of infection score was 11.95 
(SD=2.12), which indicates that participants had a moderately high level of belief in the risk 
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reduction strategies for HIV/AIDS. The distribution of individual items for the perceived 
response efficacy measure can be found in Appendix D, Table 20. 
5.2.4.5   Perceived Self-Efficacy  
The measure for perceived self-efficacy consisted of seven items that were rated on 4- point 
scale ranging (1) strongly agree to (4) strongly disagree. The perceived self efficacy scores in 
this study ranged from 13 to 28, with higher scores indicating that participants had more positive 
beliefs about their ability to reduce their sex and drug risk via safer sex and drug use practices. In 
this study, the average perceived self-efficacy score was 19.81 (SD=3.24), which indicates that 
participants had a moderate amount of belief in their own personal ability to utilize the 
HIV/AIDS risk reduction strategies. The distribution of individual items for the perceived self-
efficacy measure can be found in Appendix D, Table 20. 
5.2.4.6   Intended Risk Reduction  
The measure for risk reduction consisted of five items that were rated on 4- point scale ranging 
(1) strongly agree to (4) strongly disagree. The risk reduction scores in this study ranged from 13 
to 28, with higher scores indicating that participants had stronger intention to utilize safer sex 
and safer drug use practices. In this study, the average risk reduction score was 14.23 (SD=2.78), 
which indicates that participants had moderately strong intentions to reduce their risky HIV 
behavior. The distribution of individual items for the risk reduction measure can be found in 
Appendix D, Table 20. 
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5.2.4.7   Peer Norms 
The measure for peer norms consisted of six items. The peer norms scores in this study ranged 
from 9 to 24, with higher scores indicating that participant’s friends had stronger intentions to 
utilize safer sex and safer drug use practices. In this study, the average peer norm score was 
15.59 (SD=2.51), which indicates that participants perceived that their peers had moderate 
intentions to reduce their risky HIV behavior. The distribution of individual items for the peer 
norms measure can be found in Appendix D, Table 20. 
5.2.4.8   Cues to Action  
Data were collected regarding two possible cues to actions (external motivators). To indicate 
informational cues three yes/no items were utilized to assess whether or not the participant 
received any face-to- face information regarding HIV/AID education, had been tested for HIV 
during the previous year, and whether or not the participant had ever receive information from 
someone  encouraging them to get tested for HIV. To measure interpersonal cues two items were 
utilized to assess the number of friends or relatives the participant personally knew that had been 
infected with HIV and the number of friends or relatives that had died due to HIV disease. 
Higher scores indicate stronger cues to action.  
5.2.4.9   Informational Cues 
The informational cues to action scores in this study ranged from 0 to 3, with higher scores 
indicating that participant had stronger information cues to action. In this study, the average 
informational cues action score was 2.35 (SD=.84), which indicates that participants had 
moderately strong cues to action regarding HIV risk reduction efforts. The distribution of 
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individual items for the informational cues to action measure can be found in Appendix D, Table 
20. 
5.2.4.10 Interpersonal Cues 
The interpersonal cues to action scores in this study ranged from 0 to 2, with higher scores 
indicating that participant had stronger interpersonal cues to action. In this study, the average 
interpersonal cues action score was 1.17 (SD=.90), which indicates that participants had 
moderate interpersonal cues to action regarding HIV risk reduction efforts. The distribution of 
individual items for the interpersonal cues to action measure can be found in Appendix D, Table 
20. 
5.2.4.11 Fear (Aversive Emotion) 
The fear of HIV/AIDS was measured by one item indicating agreement with a statement 
regarding HIV/AIDS being the most frightening disease that the participant knows. The fear 
scores in this study ranged from 1 to 4, with higher scores indicating that the participant had a 
greater fear of HIV/AIDS. In this study, the fear score was 3.31 (SD=.80), which indicates that 
participants had moderately strong fear regarding HIV/AIDS.  
On the ARRM (fear scale), the normative mean for drug and alcohol clients in methadone 
treatment is 3.0 (SD=.47) (Longshore et al., 2004). In the present study, the mean fear score was 
3.31, which is approximately the same as the mean score of the comparative sample, suggesting 
that both samples have a strong fear of HIV/AIDS. The distribution of individual item for the 
fear measure can be found in Appendix D, Table 20. 
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5.3 INFERENTIAL STATISTICAL FINDINGS 
5.3.1 Bivariate Analyses 
The bivariate relationships for the primary study variables, including the ten background and 
control variables, are shown in Table 3. It is notable that the three broad outcome variables (HIV 
risk behavior, psychological dysfunction, and treatment engagement) were significantly related. 
Study findings reveal that the four bivariate research questions were significantly 
confirmed.  First, higher levels of psychological dysfunction were associated with higher HIV 
risk behavior (r=.24, p=.00). When examining psychological dysfunction and specific HIV risk 
behavior (injection, non-injection, and sexual), analyses show that higher levels of psychological 
dysfunction is associated with higher injection (r=.16, p=.02), non-injection (r=.21, p=.00), and 
sex risk (r=.21, p=.00). 
However, when examining specific psychological problems (anxiety, hostility, and 
depression) and HIV risk behavior (injection risk, non-injection risk, and sex risk), analyses 
show that hostility is positively significantly (+ p<.10, * p<.05, ** p <.01) associated with all 
types of HIV risk behavior. Correlations coefficients for these associations were .23**, .24**, 
and .27** respectively, indicating that increased level of hostility is associated with higher 
injection, non-injection, and sex risk. In addition, analyses also show that depression is 
significantly associated with non-injection drug risk (r=.14, p=.05) and marginally significant 
with injection drug risk (r=.12, p=.08) (See Table 4 for bivariate correlations among subscale 
study variables).    
Secondly, the data suggest that there is a significant negative relationship between 
treatment engagement and HIV risk behavior. Specifically, higher levels of treatment 
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engagement were associated with lower levels of HIV risk behavior (r= -.29, p=.00).  When 
examining treatment engagement and specific HIV risk behavior (injection, non-injection, and 
sexual), analyses show that higher levels of treatment engagement is associated with lower 
injection (r=-.23, p=.00,) sex risk (r= -.35, p=.00) and non-injection risk behavior (r= -.23, 
p=.00).  
When examining specific aspects of treatment engagement (treatment satisfaction, 
counseling rapport, and treatment participation) and HIV risk behavior (injection risk, non-
injection risk, and sex risk), analyses show that counseling rapport, treatment participation, and 
treatment satisfaction are significantly associated with the different types of HIV risk behavior. 
Correlations coefficients for treatment satisfaction in relationship to HIV risk behavior (sex risk, 
non-injection risk, and injection risk) were -.18** and -.13+, and -.15*, respectively, indicating 
that increased levels of treatment satisfaction were associated with lower sex, non-injection, and 
injection risk behavior.  
In addition, correlations coefficients for treatment participation and HIV risk behavior 
(sex, non-injection, and injection risk) were -.43**, -.31**, and -.29** respectively, indicating 
that higher levels of treatment participation were associated with lower sex, non-injection, and 
injection risk behavior. Correlation coefficients for counseling rapport  and HIV risk behavior 
(sex, non-injection, and injection risk) were -.28**, -.15*, and -.15* respectively, indicating that 
higher levels of counseling rapport were associated with lower sex, non-injection, and injection 
risk behavior.  
Thirdly, when examining HIV risk attitudes (ARRM Model) and HIV risk behavior, 
study findings reveal that certain ARRM constructs (perceived susceptibility, intended risk 
reduction, and peer norms) are significantly correlated to HIV risk behavior. Specifically, higher 
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levels of perceived susceptibility to HIV/AIDS were associated with higher HIV risk behavior 
(r=.26, p=.00). In addition, higher levels of intended risk reduction (r= -.31, p= .00) and peer 
norm attitudes(r=-.15, p=.04) were also associated with lower HIV behavior.  All other ARRM 
constructs (fear, HIV knowledge, cues to action, perceived risk of infection, self-efficacy, and 
response efficacy) were not significantly correlated with HIV risk behavior.   
When examining HIV risk attitudes (perceived susceptibility, intended risk reduction, and 
peer norms) in relationship to specific aspects of HIV risk behavior analyses show that perceived 
susceptibility was positively and significantly correlated with sex , non-injection, and injection 
risk behavior. Correlation coefficients were .19**, .24**, and .26** respectively, indicating that 
higher levels of perceived susceptibility were associated with higher sex, non-injection, and 
injection risk behavior. Additionally, intended risk reduction attitudes were negatively correlated 
with sex, non-injection, and injection risk behavior. Correlation coefficients for intended risk 
reduction were -.28**, -.22**, and -.28** respectively, indicating that higher levels of intended 
risk reduction attitudes were associated with lower sex, non-injection, and injection risk 
behavior. For peer norms the correlation coefficients were -.15* and -.13+, respectively, 
indicating that higher levels of peer norms were associated with lower non-injection and 
injection risk behavior.  
Finally, the bivariate analyses revealed that there is a significant relationship between 
psychological dysfunction and treatment engagement. Specifically, higher levels of 
psychological dysfunction were associated with lower treatment engagement (r= -.34, p= .00).  
When examining psychological dysfunction and specific aspects of treatment engagement 
(treatment satisfaction, counseling rapport, and treatment participation) analyses show that 
psychological dysfunction was significantly correlated with treatment satisfaction, counseling 
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rapport, and treatment participation. Correlation coefficients were -.29**, -.30**, and -.29** 
respectively, indicating that higher levels of psychological dysfunction were associated with 
lower levels of treatment satisfaction, counseling rapport, and treatment participation. 
Additionally, when examining specific aspects of psychological dysfunction (anxiety, 
hostility, and depression) and treatment engagement (treatment satisfaction, counseling rapport, 
and treatment participation), analyses show that there were significant relationships. Specifically, 
higher levels of depressive symptoms were significantly correlated with treatment satisfaction 
(r= -.22, p= .00), treatment participation (r= -.32, p= .00), and counseling rapport (r= -.24, p= 
.00). Higher levels of anxiety symptoms were also significantly correlated with treatment 
satisfaction (r= -.22, p= .00) and counseling rapport (r= -.17, p=.02). Lastly, higher levels of 
hostility symptoms were significantly correlated with treatment satisfaction (r= -.20, p= .00), 
treatment participation (r= -.23, p=.00), and counseling rapport (r= -.25, p=.00). 
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Table 3.  Bivariate Correlation Matrix Among Study Variables 
 Variables                 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
1. Gender -                 
2. -                
-               
    -             
               
 -            
 -           
                   
        
          
                
      
           
               
               
               
        
Age  .19** 
3. Time in treatment 
 
-.10  .40** 
4. Race -.17* -.47** -.12*
5. HIV risk behavior  .02 -.43** -.25**  .06 -
6. Psychological Dys  .01 -.13+ -.10  .00  .24**
7. Treatment Eng. -.00  .17*  .08  .05 -.33** -.34** 
8. HIV knowledge -.14* -.00 -.02  .03  .04 -.02 -.00 -
9. Informational Cues -.02  .09 -.04 -.11 -.08 -.03  .16* .01 - 
10. Interpersonal Cues 
 
 .00  .32**
 
 .07 -.29**  .02  .12 -.06 .15* .22** - 
 11. Perceived Susp.  .11 -.03 -.13+ -.09  .26**  .16* -.10 .06 -.07  .15* -
12. Perceived Risk  .12 -.02  .01 -.09  .10  .15* -.07 .03 -.05 
 
 .08  .38** -
13. Response Efficacy
 
-.07 -.14* -.13+  .10  .12 -.07  .09 .13+ .03 -.07  .24** -.03 - 
 14. Self-Efficacy -.11 -.02  .06  .01 -.07 -.12+  .23** .20**
 
.18* -.00 -.15* -.01 .36**
 
-
15. Intended Risk Red.
 
-.12+ 
 
 .11  .13+ -.04 -.31** -.20**  .31** -.03
 
.25**
 
-.04 -.22** -.09 .14+ .51** -
16. Peer Norms
 
-.10  .15*  .13+  .07 -.15* -.05  .24* .09 .15*
 
-.02 -.23**
 
-.18** .19**
 
.28** .34** -
17. Fear -.17*  -.09  .05  .06   .11 -.02  .04 .21** .08 -.04 -.01 -.15* .15* .21** .19** .14+ -
Note:  Dichotomous variables were coded as follows:  gender: 1 = female, 2 = male; race: 1 = African American, 2 = white 
+p#.10; *p#.05; **p#.01 
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Table 4.  Bivariate Correlation Matrix Among Subscale Study Variables 
 Variables                1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
1. Treatment Satisfaction                -
2. Counseling Rapport   .54** -              
 -             
              
    -           
     -          
    -         
  -        
          
          
           
            
          
              
            
3. Treatment Participation 
 
  .48**  .74** 
4. Anxiety -.22** -.17* -.10 -
5. Hostility -.20** -.25** -.23*   .31** 
6. Depression -.22* -.24** -.32   .36**
 
 .28**
7. Intended Risk Reduction 
 
 .23* -.21**  .36**  -.01 -.22** -.23** 
8. Perceived Susceptibility -.12* -.05 -.09   .06  .16*  .15* -.22** 
9. Peer Norms  .11  .19**  .32**   .08  .13+ -.07  .34** -.23** -
10. Sexual Risk -.18* -.28** -.43**   .09  .26**  .11 -.28**  .19** -.10 -
11. Non-Injection Risk
 
-.13+ -.15* -.31**   .10  .24**  .14+ -.22**  .24**  .15*  .59** -
12. Injection Risk -.15* -.15*  .29*   .03  .22**  .12+ -.28**  .26**  .13+  .51**  .48** -
13. HIV Risk Behavior -.19** -.25**  .43**   .10  .29**  .14* -.31**  .26** -.15*  .90**  .84**  .72** -
14. Psychological Dysfunction -.29** -.30** -.29**   .77**  .73**  .71** -.20**  .16* -.05  .21**  .21**  .16*  .24** -
15. Treatment Engagement   .81** -.89**  .86** -.19** -.27** -.31**  .31**  .10  .24** -.35** -.23** -.23** -.33** -.34** -
Note:  Due to the non-significant relationship of all other HIV risk attitudes (fear, HIV knowledge, cues to action, perceived risk of infection, self-
efficacy, and response efficacy), to subscale study variables they were not added to this correlation matrix. 
+p#.10; *p#.05; **p#.01 
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5.3.2 Regression Analyses 
First, regression analyses were used to assess what specific combination of independent 
variables, psychological dysfunction (anxiety, depression, and hostility) and treatment 
engagement (treatment satisfaction, counseling rapport, and treatment participation), best 
predicted level of HIV risk behavior (sex, non-injection, and injection risk). Secondly, regression 
analyses were utilized to assess whether or not, and to what extent, the independent variables of 
the ARRM predicted HIV risk behavior (sex, non-injection, and injection risk). Lastly, this 
method was also utilized to conduct path analyses to asses the potential mediating effects of 
treatment engagement and HIV risk reduction attitudes on the relationship between 
psychological dysfunction and HIV risk behavior.  
The regression analyses utilized to answer the first and second multivariate research 
questions involved two steps. First, in order to control for the effects of demographic variables 
on HIV Risk behavior, four variables (age, gender, race, and length of time in treatment) were 
entered as a block in the regression model. Second, psychological dysfunction (anxiety, 
depression, and hostility), and treatment engagement (treatment satisfaction, counseling rapport, 
and treatment participation), were entered simultaneously into the regression equation. However, 
when entering constructs of the ARRM Model (second question) sequential multiple regression 
analyses were utilized to enter the variables according to the different stages of the model. 
5.3.2.1   Prediction of HIV Risk Behavior 
As shown in Table 5, the four demographic variables (control variables) explained 21% of the 
variance in HIV risk behavior, F (4, 192) =13.74, p=.000. Age ($= -.51, p=.00) was a significant 
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predictor of HIV risk behavior, indicating that older methadone clients reported lower levels of 
HIV risk behavior. In addition, race ($= -.17, p=.02) was also a significant predictor of HIV risk 
behavior, indicating that white methadone clients reported lower levels of HIV risk behavior. At 
Step 2, psychological dysfunction and treatment engagement explained 27% of the variance in 
HIV risk behavior, F (6, 186) = 13.06, p= .000.  Treatment engagement was a significant 
predictor of HIV risk behavior ($= -.22, p=. 00), indicating that those who reported higher levels 
of treatment engagement had lower levels of HIV risk behavior, net of the demographics 
variables. Unlike the findings from treatment engagement, psychological dysfunction did not 
significantly predict HIV risk behavior ($= .10). 
 
 
Table 5. Multiple Regression Analyses for Predicting HIV Risk behavior 
Model  Variables    B    $        R        Adj. R5 
 
1             .48            .21 
Age    -.99 -.51**  
Gender                 3.63   .08 
Time in treatment               -.04         -.06   
Race               -8.11  -.17* 
 
2            .54         .27 
Psychological Dysfunction  .11   .10            
Treatment Engagement               -.23 -.22** 
 
Note: Dichotomous variables were coded as follows: gender: 1= female, 2= male;  
Race: 1=African American, 2=white.  
+p#.10; *p#.05; **p#.01 
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5.3.3 Prediction of HIV Risk from Specific Psychological Problems and Treatment 
Engagement (Treatment Satisfaction, Counseling Rapport, and Treatment Part.) 
As shown in Table 6, the four demographic explained 21% of the variance in HIV risk behavior, 
F (4, 188) =13.74, p=.000. Age ($= -.51, p=.00) was a significant predictor of HIV risk behavior, 
indicating that older methadone clients reported lower levels of HIV risk behavior. Race ($=.-17, 
p=.02) was also significant, indicating that white methadone clients reported lower levels of HIV 
risk behavior. At Step 2, specific aspects psychological dysfunction (anxiety, hostility, and 
depression) and treatment engagement (treatment satisfaction, counseling rapport, and treatment 
participation) explained 32% of the variance in HIV risk behavior, F (10, 182) = 10.10, p= .000.  
Hostility ($=. 18, p=. 01), and treatment participation ($= -.39, p=. 00), were significant 
predictors of HIV risk behavior. Specifically, hostility had a positive impact on HIV risk 
behavior, indicating that those who reported higher levels of hostility symptoms would be 
engaged in higher levels of HIV risk behavior. Treatment participation was also a significant 
predictor of HIV risk behavior, indicating that those who reported higher levels of treatment 
participation engaged in lower levels of HIV risk behavior. However, at this step race was no 
longer a significant predictor of HIV risk behavior. 
Similarly, treatment satisfaction was not significantly related to HIV risk behavior after 
treatment satisfaction and treatment participation are controlled.  
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Table 6. Multiple Regression Analyses for Predicting HIV Risk behavior 
 
Model  Variables    B $ R Adj. R5 
 
1             .48         .21 
Age            -.99            -.51**  
Gender            3.63             .08 
Time in treatment          -.04            -.06   
Race                       -8.11            -.17* 
       
2          .60       .32 
Anxiety           -.02              .01          
Hostility            .43               .19* 
Depression         -.06              -.02 
Treatment Satisfaction          .03               .01 
Counseling Rapport                     .32             .12 
Treatment Participation            -1.13            -.40** 
 
Note: Dichotomous variables were coded as follows: gender: 1= female, 2= male;  
Race: 1=African American, 2=white.  
+p#.10; *p#.05; **p#.01 
 
5.3.4 Predicting HIV risk behavior from ARRM Constructs 
As shown in Table, 7, the four demographic variables explained 21% of the variance in HIV risk 
behavior, F (4, 183) =13.43, p=.00. Age ($=-.51, p=.00). Age was a significant predictor of HIV 
risk behavior, indicating that older methadone clients reported lower levels of HIV risk behavior. 
Race ($= -.17, p=.02) was also a significant predictor of HIV risk behavior. At step 2, HIV 
knowledge, perceived susceptibility, and perceived risk of infection explained 25% of the 
variance in HIV risk behavior, F (7, 180) =9.79, p=.00. Perceived susceptibility was a significant 
predictor of HIV risk behavior ($=.23, p=.00), indicating that those who reported higher levels of 
perceived susceptibility to HIV were more likely to be engaged in higher levels of HIV risk 
behavior. At step 3, Informational/Interpersonal cues, response efficacy, self-efficacy, intended 
risk reduction, peer norms and fear of HIV explained 30% of variance in HIV risk behavior, F 
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(14, 173) =6.78, p=.00. Interpersonal cues were a marginally significant predictor of HIV risk 
behavior ($=.12, p=.09), indicating that those who reported higher levels of interpersonal cues to 
action would engage in higher levels of HIV risk behavior.    
Intended risk reduction attitudes also significantly predicted HIV risk behavior ($= -.28, 
p=.00), indicating that those who reported higher levels of intended risk reduction attitudes 
engaged in fewer HIV risk behaviors. Lastly, fear of HIV was a significant predictor of HIV risk 
behavior ($=.13, p=.05), indicating that those who reported higher levels of fear regarding HIV 
were those who engaged in higher levels of HIV risk behavior.    
 
Table 7. Multiple Regression Analyses for Predicting HIV Risk behavior from ARRM 
Model  Variables    B $     R     Adj. R5 
1          
             .48         .21 
Age             -.99          -.51**  
Gender            3.63            .08 
Time in treatment                        -.04           -.06   
Race           -8.11           -.17* 
          
2         .53        .25 
HIV Knowledge             .46 .04          
Perceived Susceptibility              3.85 .23** 
Perceived Risk                          -.42            -.03 
 
3          .60            .30 
Informational Cues           -.46            -.02 
Interpersonal Cues          3.08  .12+ 
Response Efficacy                         .35  .03 
Self-Efficacy             .32              .04 
Risk Reduction                          -2.40            -.28** 
Peer Norms                                   .32              .03 
              Fear                                             3.97              .13*                                           
Note: Dichotomous variables were coded as follows: gender: 1= female, 2= male;  
Race: 1=African American, 2=white.  
+p#.10; *p#.05; **p#.01 
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5.3.5 Mediating Effects of Treatment Engagement on the relationship between 
Psychological Dysfunction and HIV Risk behavior 
 
In order to examine the research question regarding the mediating effects of treatment 
engagement on psychological dysfunction and HIV risk behavior, I conducted path analyses 
using simultaneous regression model. Demographic variables, length of time in drug treatment, 
race, age, and gender were controlled for in the model test on the basis of their relationship with 
two or more central variables. For example, participants with higher scores on the HIV risk 
measure and who do not have severe psychological problems may have less time in treatment 
and therefore may not have experienced the benefits of being in drug treatment. In methadone 
maintenance treatment there is a minimum threshold of one year in order to detect favorable 
outcomes (NIH, 1999). Research suggests that if clients are in treatment for more than a year 
they are more likely to have outcomes that are more favorable on drug use and criminality 
measures (Simpson & Brown, 1997). Two of the subscales of the HIV risk measure exclusively 
examine drug use (injection and non-injection drug use). The relationship of higher scores on the 
HIV risk measure may be explained by the fact that the participants are early in the treatment or 
recovery process and may still be using or relapsing therefore exhibiting more risk behavior. 
Following Baron and Kenny (1986), I used a three-step regression procedure.                                    
In the first step, HIV risk behavior was entered as the dependent variable and 
psychological dysfunction along with the control variables were entered as independent 
variables. In the second step, treatment engagement was entered as the dependent variable and 
psychological dysfunction and the control variables were entered as independent variables. In the 
last step, HIV risk behavior was entered as the dependent variable and psychological 
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dysfunction, treatment engagement, and the control variables were entered as independent 
variables.   
The results of the mediated regression are shown in Table 8. Coefficients for each of the 
regressions are reported. The results indicate that psychological dysfunction is negatively related 
to treatment engagement (β = -.31, p < .01), which, in turn, is related to higher levels of HIV risk 
behavior (β = -.22, p < .01). Mediation is established, indicating that the effect of psychological 
dysfunction on HIV risk behavior is mediated through treatment engagement.  The Sobel Test 
indicated a significant indirect effect, (p = .008). Figure 2 shows the path analyses of the 
mediating role of drug treatment engagement in relationship to psychological dysfunction and 
drug treatment engagement.  
 
 
 
 
 
 
 
Figure 2. Results of the Path Analysis 
 
Figure 2 shows path analysis showing mediating role of drug treatment engagement in 
relation to the psychological dysfunction and HIV risk behavior. Although the control variable 
was entered in path analysis, it is not shown in Figure 2 to enhance clarity.  
 
-.21**-.31** 
Drug Treatment 
Psychological HIV Risk 
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Table 8 Multiple Regression Testing the Mediating Effects of Treatment Engagement in the 
Relationship between Psychological Dysfunction and HIV Risk Behavior   
 
Regressing HIV on Demographic Variables and Psychological Dysfunction 
 
Step1  Variables   B   $             R Adj. R5 
1         .48 .21 
Age               - .99   .51**  
Race              -8.01  -.17* 
Gender               3.63   .08 
Time in treatment              -.04          -.06 
 
2         .51       .24 
Psychological Dysfunction               .19            .17**            
 
Regressing Treatment Engagement on Demographics & Psychological Dysfunction 
               
Step 2  Variables    B $           R Adj. R5 
1                .21 .03 
Age                .46 .25**  
Race              6.67           .15+ 
Gender               -.95         -.02 
                            Time in treatment              -.01         -.02 
2              .37           .12 
Psychological Dysfunction           - .32         -.31**           
 
Regressing HIV Risk on Demographics, Psychological Dysfunction, & Treatment Engage 
Step3  Variables   B $          R            Adj. R5 
 
1              .48          .21 
Age              -.82         -.42**  
Race                                            -8.11         -.17* 
Gender             3.64           .08 
Time in treatment           -.04          -.06 
 
2              .54          .27 
Psychological Dysfunction            .11            .10          
Treatment Engagement                         -.23           -.22** 
 
Note: Dichotomous variables were coded as follows: gender: 1= female, 2= male;  
Race: 1=African American, 2=white.  
+p#.10; *p#.05; **p#.01 
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5.3.6 Mediating Effects of Risk Reduction Attitudes on the relationship between   
Psychological Dysfunction and HIV Risk behavior 
In examining the last research question of this study, psychological dysfunction was not found to 
be a significant predictor of HIV risk behavior after controlling for the selected demographic 
variables. Similarly, psychological dysfunction did not significantly predict risk reduction 
attitudes after controlling for the demographic variables (Table 9). Two of the necessary 
conditions for mediation are that the independent variable must be associated with the mediator 
variable and the associated the dependent variable. Since neither condition was met, it is safe to 
assume that risk reduction attitudes do not mediate the relationship between psychological 
dysfunction and HIV risk behavior. 
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Table 9 Multiple Regression Testing the Mediating Effects of Risk Reduction Attitudes in the Relationship 
between Psychological Dysfunction and HIV Risk Behavior   
 
Regressing HIV Risk on Demographic Variables & Psychological Dysfunction 
Step1  Variables    B $ R Adj. R² 
1                                  .48   .21 
Age                         - .99        .51**  
Race                            -8.01      -.17* 
Gender                3.63        .08 
Time in treatment                            -.04        -.06 
2         .51       .24 
Psychological Dysfunction      -.19         .17*           
Regressing Risk Reduction Attitudes on Demographics & Psychological Dysfunction 
Step 2  Variables     B $ R Adj. R² 
1         .18 .01 
Age                         - .02        .11  
Race                            - .04      -.01 
Gender               -.72       -.13 
Time in treatment                            .00        .05 
2         .25 .04 
Psychological Dysfunction                          -.02       -.17        
 
Regressing HIV Risk on Demographics, Psychological Dysfunction, & Risk Red. Attitudes 
Step3  Variables    B $ R Adj. R² 
1         .51 .24 
Age                                       - .95      -.48**  
Race                          - 7.58      -.16* 
Gender               3.51      .07 
Time in treatment                           -.04     -.05 
_____________________________________________________________________________________________ 
2         .55 .28 
Psychological Dysfunction               .14      .13*            
Risk Reduction Attitudes                                       -1.95     -.23** 
_____________________________________________________________________________________________ 
Note: Dichotomous variables were coded as follows: gender: 1= female, 2= male;  
Race: 1=African American, 2=white.  
+p#.10; *p#.05; **p#.01 
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6.0  DISCUSSION 
The main purpose of this study was to investigate the influence of psychological dysfunction and 
treatment engagement on HIV risk behavior among methadone maintained clients.  The study 
also examined the mediating role of treatment engagement and HIV risk reduction attitudes on 
HIV risk behavior.      
This chapter discusses the main findings of the study. It is divided into the following 
sections; summary and interpretation of main findings; strengths and limitations of the study; and 
implications for the social work and public health. 
6.1 SUMMARY OF MAIN FINDINGS 
This study’s findings shed light on the factors that impact HIV risk behavior among methadone 
maintained clients. The analyses revealed similarities and differences with the existing literature. 
Since many of the scales used in this study derived from the national Drug Abuse Treatment and 
Assessment Resources Study (DATAR), I will compare my findings to their 2001 results, as well 
as to other pertinent studies. 
The current study found that about 60% of the participants had experienced moderate to 
high levels of psychological dysfunction. When examining specific aspects of psychological 
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dysfunction, 76.5% experienced moderate to high depressive symptoms, 53.5% experienced 
moderate to high hostility symptoms, and 73% experienced moderate to high anxiety symptoms.  
Compared to means for depression, anxiety, and hostility from DATAR (2001), 
respondents in the study experienced higher levels of anxiety (31.3 vs. 28.4) symptoms but 
roughly comparable levels of hostility (24.4 vs. 23.4) and depressive (25.7 vs. 25.5) symptoms.  
When the results are compared to DATAR findings for the percent of clients reporting 
problems with psycho-social functioning during treatment this sample reported significantly 
higher rates of problems. Specifically, participants scoring higher than 30 on any of the 
psychological dysfunction measures are considered to have problems associated to the specific 
disorder. This study’s results revealed that this sample reported 25%, 42.5%, and 53% 
respectively for problems associated with hostility, depression, and anxiety. However, results 
from the DATAR reveal that clients nationally have fewer problems with percentages at 21%, 
26%, and 38% respectively for hostility, depression, and anxiety. These findings are particularly 
high for the study’s respondents and may suggest the need for interventions that address 
psychological problems among clients enrolled in methadone drug treatment (Simpson, 2001). 
The current study found that participants were less engaged in their treatment process. 
When compared to national data from DATAR, the percentage of the sample scoring high on 
treatment engagement scales were significantly lower. Specifically, scores over 40 are 
considered to be high (Simpson, 2001).  Finding from this study indicate that only 23%, 30%, 
and 31% respectively reported high treatment satisfaction, counseling rapport, and treatment 
participation. However, the national sample reported 34%, 50%, and 53% respectively on high 
treatment satisfaction, counseling rapport, and treatment participation.  When comparing this 
study’s mean scores on the treatment engagement scales the scores are quite comparable to 
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national data.  Specifically, for treatment satisfaction (36.0 vs. 37.8) scores were slightly lower 
but indicating that participants were satisfied with treatment. Scores on treatment participation 
(37.7 vs. 40.6) and counseling rapport (36.6 vs. 39.6) were also slightly lower but still indicating 
that the sample had moderate participation in treatment and moderate rates of counseling rapport 
(Simpson, 2001). 
The current study found psychological dysfunction to be moderately and significantly 
correlated to treatment engagement (treatment satisfaction, counseling rapport, and treatment 
participation), indicating that those who reported high levels of psychological dysfunction also 
reported low levels of treatment engagement.  
This finding is mixed when compared with other studies that assessed psychological 
problems and treatment engagement. Specifically, Joe, Brown and Simpson (1995), found that 
clients with higher levels of psychological problems were more likely than those with fewer 
psychological problems to participate in drug treatment (attend recommended counseling session 
per month) and were more likely to discuss psychological issues in their counseling sessions. 
However, other research suggests that clients with increased rates of psychological problems 
perform worst during treatment (Woody et al., 1997).  In addition, the complexity and severity of 
psychological problems are said to hinder efforts to reduce drug use and impact the participation 
in drug treatment (Simpson, 2001).  
The prevalence of injection drug use was moderately high among participants in this 
study. Injection drug use accounts for one-third of all new diagnosed HIV persons. Almost half 
(45.5%) of the participants reported injection drug use during the 3 months prior to the study.  
The rates of injection drug use among this sample are consistent with earlier reports of injection 
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drug use in methadone maintenance clients (Camacho et al., 1996; Bux et al., 1995; Ball et al., 
1988).  
Of those that injected, 19% injected more than 10 times and 26.5% injected between 6-10 
times during the past 3 months. Nineteen percent of the sample reported that they shared needles 
and of those that shared needles, 16% reported sharing with 1 or more persons.  Other studies 
have reported sample sharing at rates of 6% - 47.5 % (Camacho et al., 1996; Bux et al., 1995; 
Darke, et al., 1990; Donoghoe et al., 1989). When comparing this study’s needle sharing rates 
with another Pennsylvania study utilizing methadone clients, this sample shared needles at a 
much higher rate (19% vs. 6%). Finally, given that needle sharing is taking place among 
injection drug users, cleaning practices are of grave importance, with evidence existing from this 
study that cleaning practice are far from adequate. Thus, while 40% of the sample claimed that 
they always cleaned their needles before re-using, only 23.6% used bleach every time.  
In addition to injection drug use, the prevalence of non-injection drug use was also 
extremely high. Almost the entire sample (97%) reported that they smoked, snorted, sniffed, or 
took orally some kind of drug. The drugs most commonly used drugs were: alcohol (54%), 
prescription medications (50%) (i.e., Xanax, Klonopin, and Valium), marijuana (45%), heroin 
(44%), and crack cocaine (43%). Almost half the sample reported being drunk one or more times 
during the three months prior to the study.  When compared to the other study in Pennsylvania 
utilizing the methadone this sample reported more drug use (Bux et al., 1995). Specifically, this 
sample used more alcohol (54% vs. 47%), prescription medications (50% vs. 26%),  heroin (44% 
vs. 40%), and crack cocaine (43% vs. 32%).  
This study’s bivariate correlation findings indicated that high levels of non-injection drug 
use are associated with high levels of psychological dysfunction. Additionally, findings revealed 
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that increased levels of non-injection drug use are also associated with low levels of treatment 
engagement. These findings are congruent with the existing literature (Camacho et al., 1996; Joe 
et al, 1995; Simpson et al. 1993).  
Of the entire sample, 78% of the participants had engaged in sex in the previous 3 
months. Overall, 22.5% of the participants had more than one sex partner in the previous 3 
months.  Thirty percent of the subjects had engaged in prostitution during this period. These 
findings are somewhat different than the other PA study. Specifically, this sample engaged in 
higher rates of sex (78% vs.67%), prostitution (30% vs. 3%), and had greater rates of having sex 
with more than one sex partner (22.5% vs. 6%) (Bux et al., 1995). 
Almost half (45%) of the participants who had a regular partner had not used condoms 
with their partner during the study period. Only 27% had always used a condom with their 
regular partner. Nearly half (49%) of the participants had engaged in sex with a casual partner. 
Of these participants, 27.5% never used a condom, with 41.8% always having used a condom. Of 
all of the participants who had engaged in prostitution only one-third (31.7%) reported using 
condoms all of the time. This rate is significantly higher than other studies assessing HIV risk 
behavior (Camacho et al., 1996; Bux et al., 1995). A sizeable portion of participants had engaged 
in oral sex (69.5%) and anal sex (18.5%) in the 3 months preceding the study. Ten percent 
(N=20) of the respondents reported that they had tested positive for HIV. 
This study’s bivariate correlation findings indicated that high levels of sexual risk 
behavior are associated with high levels of psychological dysfunction. Additionally, findings 
reveal that increased levels of sexual risk behavior are also associated with low levels of 
treatment engagement. These findings are congruent with the existing literature (Latkin et al., 
2004; Camacho et al., 1996; Joe et al., 1991; Simpson et al., 1993). 
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6.1.1 Assessing the Study’s Main Research Questions 
In this study, I explored several research questions; however, for my discussion I will focus my 
assessment around my three main questions. The first main research question examined various 
psychological, ARRM, and treatment engagement variables in the terms of their impact on HIV 
risk behavior. The second main question examined the mediating effect of treatment engagement 
on HIV risk behavior. The third main question examined the mediating effect of risk reduction 
attitudes on HIV risk behavior. There were two versions of the independent variables used in 
theses analyses:  an overall version of psychological dysfunction and treatment engagement and 
the subscale version of each of these versions. 
With respect to the first research question, assessing overall psychological dysfunction 
and treatment engagement on HIV risk behavior; only treatment engagement was a significant 
predictor of HIV risk behavior net of demographics and control variables. This finding suggests 
that high levels of treatment engagement predict lower levels of HIV risk behavior.  
When assessing the specific subscales of psychological dysfunction (hostility, anxiety, 
and depression) and treatment engagement (treatment satisfaction, counseling rapport, and 
treatment participation) on HIV risk behavior, two (hostility and treatment participation) out of 
the six variables were significant predictors of HIV risk behavior.   Specifically, hostility ($= 
.19, p= #.05) was a significant predictor of HIV risk behavior, indicating that increased levels of 
hostility symptoms predict high levels of HIV risk behavior.  In addition, treatment participation 
($= .-.40, p= #.01)  was a significant predictor of HIV risk behavior, indicating that increased 
levels of treatment participation predicts low levels of HIV risk behavior. The reasons that the 
other variables did not predict HIV risk behavior significantly, may be attributed to the fact that 
the variables are highly correlated with a number of other variables in the regression model.  
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The second research question assessed the impact of the ARRM variables on predicting 
HIV risk behavior. Four (perceived susceptibility, interpersonal cues, risk reduction, and fear) 
out of 10 ARRM variables significantly predicted HIV risk behavior. Findings suggest that those 
who reported higher levels of perceived susceptibility fear, and interpersonal cues also reported 
higher levels of HIV risk behavior. In addition, higher levels of intended risk reduction attitudes 
also predicted lower levels of HIV risk behaviors. These variables explained 28% of the total 
variance in HIV risk behavior.  
Lastly, this study attempted to assess whether or not drug treatment engagement and risk 
reduction attitudes mediated the relationship between psychological dysfunction and HIV risk 
behavior. Results indicated that the effect of psychological dysfunction on HIV risk is mediated 
through treatment engagement but risk reduction attitudes did not mediate the relationship 
between psychological dysfunction and HIV risk behavior. These findings extend the current 
literature in that previous studies do not assess the impact of mediators on the relationship 
between psychological dysfunction and HIV risk behavior.  
6.2 STRENGTHS AND LIMITATIONS OF THE STUDY 
The present study attempted to address several important limitations and gaps in the literature on 
the relationship between psychological dysfunction and HIV risk behavior. These gaps and 
limitations focus on measurement, mediators, and research design. The specific limitations that 
the study sought to address include the following:  First, previous research examining the role of 
psychological dysfunction, treatment engagement, and ARRM variables on HIV risk behaviors 
have used various types of HIV risk behavior measures (Robinson & Evans, 1999; Samuel et al., 
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1993; Simpson, Knight, & Ray, 1993). Most studies address only a single aspect of HIV risk 
behavior such as sexual behavior or injection drug use. Additionally, many studies only utilize a 
single measure of occurrence of unprotected sex/or number of sex partners or a single occurrence 
of injection drug use/ or number of times sharing needles. This study focused on a more 
comprehensive model of HIV risk behavior, which is indicative of substance abusing populations 
(sexual behaviors, non-injection drug use/alcohol use, and injection drug use).  
Second, this study utilized a composite index that combined unprotected sexual risk with 
the number of sex partners, injection frequency with sharing needles, and non-injection drug use 
such as smoking crack/snorting cocaine or using prescription drugs such as benzodiazepines or 
oxycodone. Utilizing this type of measure increased the likelihood that the instrument was more 
sensitive in detecting the association between psychological dysfunction and a composite 
measure of HIV risk behavior rather than a single measure of an occurring risk behavior. 
Third, this study had a relatively strong design in respect to the temporal relationship 
between the measures, which perhaps aided in the strength of the statistical associations. The 
psychological dysfunction, drug treatment engagement, and the HIV risk behavior measures 
assessed affect and behavior in the past 3 month. Prior studies have assessed affect in past week 
and behavior in past month, which may have diminished the strength of association in past 
studies. 
Despite its strengths, this study has several limitations that should be discussed. The first 
two limitations relate to the use of self-reporting of highly sensitive information. First, the 
reliance on self-report measures of all central study variables are a cause for concern in regard to 
the internal validity of the relationships due to response distortions (over or under reporting, 
recall error, and social desirability). For example, participants may have had problems disclosing 
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sensitive information. Many participants may have not wanted to give an honest account of their 
sexual behavior such as having anal sex or trading sex for drugs or money, which is common 
among this population. A second limitation of the study is that it was conducted on site at a 
methadone treatment facility. Some participants may have felt that they could not be completely 
honest in reporting their drug use due to the fear (e.g. possible punitive sanctions for continued 
drug use) or that their confidentiality would not be protected.  To address this problem I made 
every attempt to ensure participants that their confidentiality and anonymity would be protected 
(no identifying information was put on the survey and the study was conducted in a private 
location within the treatment facility). Despite these concerns, relatively large proportions of the 
sample did admit to these behaviors. These high proportions suggest that participants felt at least 
somewhat comfortable sharing this sensitive information. 
A third limitation of the study is the cross-sectional research design. Because the study is 
cross-sectional, the results cannot definitively establish causality. It is important to note that, 
although the theoretical context introduced earlier suggests that psychological dysfunction may 
promote HIV risk behavior and that my data are consistent with the proposed model, there is a 
possibility that the casual direction may also run in the opposite direction. That is HIV risk 
behavior may cause increased levels of psychological dysfunction. Data collected over time 
(longitudinally) from the same respondents would provide an empirically stronger test of the 
model. An additional potential limitation of the study is that it makes an assumption regarding 
the external impact of the services being offered at the treatment facility. It is not certain that 
services offered at the treatment facility were evenly distributed among clients participating in 
the study and it’s impossible to know whether or not clients received the same quality and level 
of counseling services. Research suggests that the therapist/counselor is a significant factor in 
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determining treatment outcomes. Therapists who have strong interpersonal skills such as 
empathy and have the ability to forge therapeutic alliances/counseling rapport are reported to 
have better treatment outcomes (Najavitis & Weiss, 1994). Furthermore, there were contextual 
differences (i.e., community differences-high crime rates, community violence, high-rates of 
drug abuse, and drug availability) among the clients participating in this study that could have 
had an impact on the outcome of the study’s results. 
Finally, there is at the least one unaddressed threat to the external validity of this study. 
The sample utilized for this study is a purposive sample and is limited to participants of one 
methadone treatment facility. This sampling strategy limits the sample to individuals who are 
only enrolled in methadone treatment. Thus, the findings might not be generalizeable to others 
enrolled in other types of drug treatment modalities (out-patient (drug-free), residential, partial 
hospitalization) or to methadone clients in other locations. 
6.3 IMPLICATIONS FOR SOCIAL WORK POLICY, PRACTICE, AND DELIVERY  
Despite the limitations of this study, the current study makes a significant contribution to the 
existing literature. There is scant research on the HIV risk taking behavior of individuals who are 
addicted to opiates and have psychological problems. While there have been several studies on 
individuals addicted to opiates and the problems that they face, there has been little research that 
examines the predictors of HIV risk behavior among this population. Most studies do not assess 
HIV risk in a holistic manner (i.e., injection drug use, non-injection, and sexual risk behavior); 
however, this study has built upon the existing gaps and has found that there is a significant 
83 
relationship between psychological dysfunction, drug treatment engagement, and HIV risk 
behavior. 
A continued detailed research on this population could provide public health officials, 
drug treatment professionals, and social workers with the opportunity to identify and modify the 
predictors of HIV risk behavior, which can help prevent or reduce the transmission of blood born 
viruses and ultimately save lives. Given the importance of injection drug use, non-injection drug 
use (e.g., crack pipes), and sexual behavior as routes of HIV transmission, there is an irrefutable 
need for risk reduction research and interventions to prevent and reduce the spread of blood born 
viruses among this population.  
The results of this study suggest that there is also a need to screen and treat clients for 
psychological problems. Specifically, MMT programs should develop an effective early 
screening, assessment, referral, and psychiatric treatment system for clients enrolled in their 
treatment programs. Additionally, data suggest that psychological problems decrease methadone 
clients’ drug treatment engagement (therapeutic relationship with counselor) and in turn, increase 
their HIV risk behavior. Therefore, counselors at methadone clinics must develop successful 
therapeutic relationships with all clients, but more specifically with clients who have 
psychological problems. According to the Center for Substance Abuse Treatment (CSAT), there 
is an association between the strength of the therapeutic alliance and counseling effectiveness. 
Research suggests therapeutic alliances are strong predictors of treatment participation, drinking 
behavior during treatment, and drinking behavior 12 months after treatment among outpatient 
alcoholic clients (Conners et al., 1997). Additionally, another study among opiate dependent 
clients with moderate to severe psychological problems, found that fewer than 25 percent of 
those with weak therapeutic alliances completed treatment, while more than 75 percent of those 
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with strong therapeutic alliances completed treatment (Petry and Bickel 1999). Methadone 
treatment counselors should follow the recommended guidelines developed by CSAT for 
regarding successful therapeutic techniques when working with clients with psychological 
problems. The guidelines are as follows: (1) develop and use a therapeutic alliance to engage 
clients in treatment, (2) maintain a recovery perspective, (3) manage countertransference, (4) 
monitor psychiatric symptoms, (5) use supportive and empathic counseling, (6) employ 
culturally appropriate counseling methods, and (7) increase structure and support for clients with 
psychological problems.  
In addition these data suggest that in the midst of the HIV/AIDS epidemic, it is not 
sufficient for methadone programs and social workers to focus on whether or not the client has 
relapsed (drug use). In line with Metzger et al. (1991), counseling that includes discussion on 
overall high-risk behaviors is warranted. MMT counseling should incorporate HIV risk reduction 
plans that thoroughly examine not only injection drug risk behaviors but also those that examine 
sexual and non-injection drug risk behaviors. Methadone treatment providers (social workers and 
public health workers) must be trained in HIV risk reduction counseling and effective counseling 
methods for treatment of clients with psychological problems; even if many may feel that 
acknowledging such risky behaviors implies that the agency is accepting of drug use. These 
discussions are a crucial part of counseling and may provide opportunities for methadone clients 
to engage with the counselors on a deeper level and evaluate their risky behavior on a continuous 
basis. This continuous evaluation may provide opportunities for clients to modify their risky 
behavior.  
The association between psychological dysfunction and drug treatment engagement, and 
the potential for these to be associated with increased rates of HIV risk behavior, has implication 
85 
for both drug treatment and HIV prevention efforts. As stated earlier, the data suggest the 
importance of early screening and treatment of psychological problems. Modifying 
psychological problems has the potential to impact the therapeutic relationship in a positive 
direction and potentially impact methadone clients overall HIV risk behavior.  Concerning HIV 
prevention counseling, the data also suggest the need to assess clients for psychological problems 
because many clients engage in risky behaviors to alleviate the symptoms related to 
psychological problems (Morris & Reilly, 198; McKirnan et al., 1996).  
Furthermore, policy makers need to provide additional resources to drug treatment and 
prevention programs so that they can provide comprehensive treatment services for clients with 
psychological problems (i.e., screening and assessment, mental and physical health 
consultations, on-site prescribing psychiatrist, medication monitoring, psycho-educational 
classes, and onsite dual recovery groups and self-help meetings). Social workers and public 
health officials should advocate for comprehensive services on the behalf of drug treatment 
clients. If resources were not available to provide comprehensive treatment services for clients, it 
would be imperative that counselors provide referrals to mental health care and other needed 
services. Research suggests that when clients have unmet psychiatric and other needs their ability 
to focus on their recovery can be compromised. However, when programs match the individual 
treatment needs of clients to treatment services that address those needs, outcomes are improved 
(Hser et al., 1999; McLellan, 1998, 1999). Thus, by providing comprehensive services, treatment 
agencies have the capacity to improve outcomes and reduce the ills associated with drug usage. 
Research suggests that for every $1 spent on addiction treatment more than $7 in future costs are 
saved. When addiction is left untreated (with its links to mental health, illness, and crime) it cost 
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individuals, families, and society an estimated $20 billion each year (National Institutes of 
Health, 1997).  
Lastly, interventions that address HIV risk behavior among methadone client with 
psychological problems should assess and attempt to reduce psychological problems among its 
participants. By doing so, the intervention may be more efficacious in reducing risk behavior and 
hence HIV transmission. NIDA’s Principles of Drug Addiction Treatment notes that “matching 
treatment settings, interventions, and services to each individual’s particular problems and needs 
is critical to his or her ultimate success in returning to productive functioning in the family, 
workplace, and society” (NIDA, 1999, p.3).  Given that this study found that methadone clients 
were experiencing significant problems as it relates mental health, HIV risk, and treatment 
engagement it is imperative that drug treatment programs consider the implications of such 
problems. Implementing such strategies suggested by NIDA and CSAT may improve treatment 
outcomes among methadone maintained clients and may garner increase support from opponents 
that dismiss methadone maintenance treatment as a useless, addictive narcotic substitution 
therapy. 
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APPENDIX B 
TADISO, INC. PERMISSION LETTER FIRST PARAGRAPH. 
 
 
 
January 5, 2007 
 
Institutional Review Board (University of Pittsburgh): 
 
We, Tadiso, Inc., authorize Latika Davis-Jones the right to conduct research at our main 
facility located at 1425 Beaver Avenue Pittsburgh, PA. We are in total support of Latika’s efforts 
and welcome the opportunity to learn more about the population that we serve. 
 
Thank you, 
 
Taru J. Cook, MA, CAC 
Chief Operating Officer 
Tadiso, Inc. 
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APPENDIX C 
RECRUITMENT LETTER/SURVEY INSTRUMENT 
 
 
 
 
 
 
 
Winter/Spring 2007 
 
Dear Tadiso Client: 
 
Drug and alcohol problems affect many people each year. I am interested in learning about you and your 
drug treatment process and will be conducting a survey at your treatment facility for this purpose. I will 
need to collect information about your drug treatment experiences, drug use, and sexual behavior. A few 
questions are highly personal; however all information will be kept confidential. 
 
I anticipate that this study will be helpful to drug & alcohol treatment providers in developing treatment 
strategies and prevention/intervention strategies for individuals like you.   
 
This survey will take about 20 minutes to complete. This research is totally voluntary and anonymous. 
Your responses will be kept in strict confidence. For your protection all information will be stored in a 
secure database and your information will be kept in a locked file. I am asking that you do not put your 
name or client ID number on any of the pages of the survey in order to keep your identity completely 
anonymous. Participation in the study is voluntary and no way tied to your ability to receive 
services/methadone at Tadiso, Inc. If at anytime throughout the study you begin to feel uncomfortable 
you have the right to decide not to participate.  
 
Upon completion participants will be compensated $5 dollars for their time. If you have any additional 
question, please call Latika Davis-Jones, MSW at 412-362-8510 Ext. 10. 
I look forward to working with you and thank you in advance for your assistance. 
 
      Sincerely, 
      Latika Davis-Jones, MSW, Ph.D Student 
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